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Abstract 
Human immunoglobulin (Ig) G is the most commonly found class of antibody in the human body 
and is involved in pathogen recognition as a part of the adaptive and innate immune response. 
Recognition occurs through the fragment antibody binding (FAB) region and interaction with the 
innate immune system occurs via interactions between the fragment crystallisable (Fc) region and 
cell surface Fc receptors as well as select proteins of the complement system. It is this interaction 
that allows IgG to activate the immune system.  The aim of this work was to characterise, at the 
atomic level, the recognition of heparin analogues using IgG-Fc fragments.  
One native crystal structure of purified IgG-Fc and two crystal structures of heparin soaked IgG were 
determined, one with purified IgG-Fc soaked in heparin of size degree of polymerisation (dp) 12 and 
a recombinant IgG-Fc soaked in a rough heparin fraction. These structures have been successfully 
solved in P212121 using rigid body refinement. The native purified IgG-Fc was refined to 2.30 A
ͦ
, 
with refinement statistics: Rwork 0.296 and Rfree 0.356. And the dp12-soaked purified IgG-Fc was 
refined to 2.15 A
ͦ
 with refinement statistics: Rwork 0.250 and Rfree 0.301. The rough heparin-soaked 
recombinant IgG-Fc was refined to 3.55 A
ͦ
 with refinement statistics: Rwork 0.325 and Rfree 0.297. 
Whilst no ligand binding was observed in the heparin soaked structures, the N-linked glycan of the 
Fc region is clearly defined.  
The proportions of IgG subtypes in the human sera sample were also characterised through the use 
of matrix assisted laser desorption/ionisation (MALDI) and electrospray ionisation (ESI) mass 
spectrometry. Using these techniques, the sequence coverage of IgG-Fc subtypes in the sample of 
purified human sera used in this work were found to be: 84.5% IgG1-Fc, 28.2% IgG2-Fc, 12.1% 
IgG3-Fc and 11.3% IgG4-Fc respectively. 
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Chapter 1 – Introduction and Background 
1.1  The Immune System 
The immune system is the most important factor in maintaining the integrity of host defence against 
the harmful pathogens to which the body is exposed almost constantly. To this end it has evolved a 
vast array protective mechanisms which enable it to control and remove these pathogens and the 
harmful toxins that they produce. The immune system is divided into two equally important halves 
called the adaptive and the innate immune systems, these names are derived from the specificity and 
mechanism of their actions. Whilst these two systems are very distinct there is actually frequent 
interaction between the two; the innate immune system encompasses the parts of the immune system 
such as neutrophils, monocytes, macrophages and the complement system and immediately respond 
to threats to the survival of an organism. Due to the fact that the immune system of invertebrates 
consist solely of innate immune system and because the components of innate immunity are highly 
conserved between both vertebrates and invertebrates; it can be deduced that it is extremely 
important for fighting off infections. The adaptive immune system is only found in higher animals 
such as humans and consists of specific antigen responses brought about by T- lymphocytes and B-
lymphocytes. The T-lymphocytes or T-cells are characterised by their surface expression of the αβT-
cell receptor (TCR) whose primary function is to recognise antigens in complex with class I and II 
MHC proteins. These mature T-cells can differentiate into several mature sub-types all of which 
have different functions and targets: CD8 T-cells target cells which are intracellularly infected, CD4 
T-cells regulate the cellular and humoral immune responses such as activation of the B-lymphocytes. 
The smallest group are the natural killer cells which target cells that present glycolipid antigens 
which are presented by the CD1d molecules. This particular type of T-cell is characterised by its 
ability to rapidly produce large numbers of cytokines. The B-lymphocytes or B-cells make up about 
15% of the blood leukocyte concentrations and are defined by their secretion of antibodies. B-cells 
mature from haematopoietic stem cells within the bone marrow and it is here that they produce their 
antibodies. B-cells can become activated by T-cells during an infection by a pathogen, this activation 
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causes them to mature which induces isotype switching in the antibodies produced by the B-cells by 
T-cell cytokines. This allows the T-cells to control this switching as well as the type of antibody 
produced. Isotype switching has been heavily associated with the B-cell memory response which 
allows for rapid production of antibodies in the event of secondary infection, it is the memory 
response which makes vaccination so important and effective. The innate immune response is 
characterised by a rapid but non-specific response which has the potential to damage healthy host 
tissues; the adaptive immune system is characterised by a slow but highly specific response. Whilst 
the initial response of the adaptive immune system is slow its memory allows its response to 
subsequent infections to be far more rapid however they are still not as immediate as the innate 
response. This lag period associated with the adaptive immune system highlights the importance of 
the interactions of the two systems (Delves 2017; Lawrence 2010).  
1.1.1  An Introduction to Antibodies 
Antibodies, also known as immunoglobulins (Ig), are the secreted form of B-cell receptors. They 
make up part of the immunoglobulin superfamily alongside other cell surface recognition proteins 
such as MHC Class I and II proteins. These proteins are soluble and make up 10%-20% of the total 
plasma content within human serum. These immune proteins are Y-shaped and made up of three 
recognisable components: two arm regions and a stem region (figure 1.1). The arms are referred to 
as the variable regions due to their large intermolecular variation, which is required in order for them 
to perform as antigen binders. The stem interacts with and binds to effector molecules of IgG; such 
as C1q receptors. Each Ig monomer is made up of these three domains; which are in turn made up 
of 4 protein chains: 2 heavy chains which have a Mr of 50 KDa each and 2 light chains which have 
and Mr of 25 KDa each. Both of the heavy chains are identical to each other and both of the light 
chains are identical to each other. Both of the light chains are associated with a different heavy chain; 
this produces two identical chains which consist of both a light chain and a heavy chain; it is this 
symmetry that gives Igs their two identical antigen binding sites. These multiple identical binding 
sites allow for greater binding affinity and strength of the antibody/antigen interaction due to the 
multiple contact points they provide (Vidarsson et al, 2014).   
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Figure 1.1 – The basic structure of an IgG antibody. The light chains of the variable domains are shown in 
purple and green and the heavy chains of both the variable and constant domains are shown in blue and red. 
1.1.2  Overview of IgG  
IgG is one of the most abundant proteins found in human serum making up about 10%-20% of the 
total plasma content. It is also the most abundant of the five human antibody classes: IgM, IgD, IgG, 
IgA and IgE. These glycoproteins are roughly composed of 82-96% protein and 4-18% carbohydrate 
in the form of an N-linked glycan at the Asn297 residue. There are a further four subclasses of IgG: 
IgG1, IgG2, IgG3 and IgG4; they are named in order of decreasing abundance and were first 
discovered in the 1960s through studies using specific rabbit antisera against human IgG proteins. 
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Whilst they are 90% identical on the amino acid level, they all have a unique profile for antigen 
binding, effector binding and half-lives. The heavy chain structures of the different subclasses of 
IgG are marginally different to each other and because of this their effector functions differ (Schur 
1988).  The different subclasses respond to different types of antigens as well as initiating different 
responses caused by different secondary signals which influence the differentiation of the B-cells, 
including recognition by pattern-recognition receptors. IgG1 is the most common type of antibody 
found within the body. As with all IgG1 subtypes they respond to soluble protein antigens/ 
membrane proteins however they are usually accompanied by lower levels of IgG3 and IgG4 
(Ferrante et al. 1990). Due to the usually high abundance of IgG1, a lack of IgG1 present in primary 
and secondary infections can possibly result in a decrease in total IgG levels which can be associated 
with recurrent infections (Jefferis & Kumararatne 1990). The IgG2 subclass respond exclusively to 
the bacterial capsular polysaccharides (Ferrante et al. 1990; Barrett & Ayoub 1986; Schauer et al. 
2003). A deficiency of this subclass can result in the absence of IgG anti-carbohydrate antibodies 
(Hammarstrom et al. 1983) however this response can be compensated for by a higher level of the 
IgG1 and IgG3 subclasses (Hammarstrom et al. 1987). This deficiency is also linked to an increased 
susceptibility to certain bacterial infections which implies that IgG2 has a role in defence against 
these bacteria (Kuijpers et al. 1992; Siber et al. 1980). Whilst the majority of glycan infections are 
reacted to by IgG2 there have been cases of IgG1 antibodies working against Haemophilus 
influenzae b polysaccharide (Ferrante et al. 1990). In normal immune responses IgG1 and IgG3 can 
also be observed especially against protein-conjugated glycans. IgG3 is particularly effective at the 
induction of effectors, they are pro-inflammatory antibody and as such its shorter half-lives can limit 
the potential of inflammatory responses (Stapleton et al. 2011). IgG4 is most often induced following 
repeat, long-term exposure to antigens in non-infectious settings such as those found on allergens 
(Aalberse et al. 1983).  
1.1.3  Structural Details and Features of IgG  
Igs are Y-shaped molecules, made up of a variable and a constant region which are split into six 
recognisable domains: The heavy variable (VH), light variable (VL), light constant (CL), heavy 
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constant 1 (CH1), heavy constant 2 (CH2) and heavy constant 3 (CH3) domains. These six domains 
are made up of the two identical light chains which make up the VL and CL domains and two 
identical heavy chains which make up the VH, CH1, CH2 and CH3 domains (Vidarsson, Dekkers 
and Rispens, 2014). The first 110 residues of the light chains as well as the first 110 residues of the 
heavy chains make up the VL and VH1 domains respectively which along with the next 110 residues 
of the light and heavy chains make up the CL and CH1 domains respectively. Together these four 
domains make up the Fragment Antigen Binding (FAB region) of the Igs. The final 220 residues of 
the heavy chain make up the CH2 and CH3 domains which make up the Fragment Crystallisable (Fc 
region) of the Ig and contain several binding sites for effector molecules such as C1q receptors. 
These multiple identical binding sites allow for greater binding affinity and strength of the 
antibody/antigen interaction due to the multiple contact points they provide (Potter, 1983; Vidarsson, 
Dekkers and Rispens, 2014). The light chains as well as the short N-terminal variable region of the 
heavy chains make up the antigen recognising domain of the Fragment antigen binding (FAB) 
region.  The preceding 50 residues of the heavy chain then make up the remainder of the CH1 
domain. The structure of these domains are shown in figure 1.2. 
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Figure 1.2 – The basic structure of an IgG antibody. The structure of a human IgG1 antibody. The light 
chains of the variable domains are shown in purple and green and the heavy chains of both the variable and 
constant domains are shown in blue and red. The N-linked glycosylation of the Fc region is shown in 
Glycoblocks form. Produced in CCP4mg. PDB code (1IGT). 
The CH1 domains of the FAB region have properties that allow them to recognise and bind antigens. 
The Fc contains no antigen binding activity but crystallises readily (Schur. 1988). The two paired 
heavy chains within this region interact with effector molecules such as C1q, the functional 
differences between the different isotypes are due to differences in the Fc region (as addressed 
below). The receptors found on T cells and B cells are called Fcγ(Gamma) receptors. One of these 
receptors is the FcγRIIB-1 located on B cells which binds to the Fc region of IgG antibodies and 
causes the activation of the B cell once the antigens have been bound (Schur 1988). 
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Another important functional region of Igs is the hinge region which is located between the CH2 and 
CH1 domain. The hinge is a three part structure consisting of an upper, middle and lower section. 
The upper section is defined as a peptide bridge that stretches from the N-terminal of the CH1 domain 
to the first Cys (226) residue in the hinge region. This upper section is conserved between subtypes 
and importantly forms an interchain disulfide bond. Another disulfide bond is formed between the 
Cys220 residue on the hinge and one of the light chains. The upper section of the hinge region also 
has a very low structural stability and is very accessible to solvent. This allows the hinge region and 
FAB regions to flex, aiding in their antigen binding properties. The middle region of the hinge 
consists of residues from the C-terminal of the upper hinge to the Ala231 residue in the lower hinge. 
This region contains multiple Cys residues all of which are responsible for forming the intra-chain 
disulfide bonds which provide rigidity to the hinge. Proline residues surround these Cys residues and 
form a polyproline helix which provides flexibility to the hinge region as well as maintaining its 3D 
structure; this flexibility comes from the lack of a fixed pattern of intra-chain hydrogen bonds as this 
allows conformational changes within the structure. The lower hinge is encoded by a separate exon 
to the upper and middle regions (Brekke et al. 1995). X-ray crystallography and NMR studies have 
shown that there is a lack of significant electron density in this region, this is theorised to be due to 
a significant degree of movement within this region which implies that it is this region which 
provides the Fc with its flexibility. The lower hinge is also the site of FcγR binding and as such is 
involved in the interaction between Igs and the cell surface (Vidarsson et al. 2014). The hinge region 
is also known to be involved with not only the antigen binding properties of IgG by allowing them 
to bind to differently spaced antigens through the flexibility they provide; but they are also known 
to directly influence the binding of C1q and the activation of the complement system, it is assumed 
that the overall flexibility of the hinge region is required to allow the Fc region to adopt an optimum 
conformation for C1q binding. The flexibility is also important as it ensures that the Fab arms can 
move out of the way of the C1q binding site to prevent them from blocking access to the binding 
site. It has been suggested that one of the functions of the hinge region is to hold the CH2-CH3 
domains of the Fc region in the optimum orientation for FcγRIIB binding rather than through direct 
hinge FcγR interaction. The light chain also consists of a variable N-terminal domain and a constant 
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C-terminal domain, which have identical sequences to N and C-terminal domains of the associated 
heavy chain. Structural studies of the Ig heavy and light chains have determined that each chain 
consists of similar sequences of about 110 amino acids long. The repeats found within these 
sequences correspond to discrete folded regions of the protein known as an immunoglobulin fold/ 
domain (whose structure is discussed below). The light chain is made of two of these domains and 
the heavy chains are made up of four. The amino terminal amino acids of the heavy and light chains 
vary between different antibodies; this variability is limited to the first 110 amino acids of the first 
domain (VL & VH domains), the remaining domains are conserved between Ig chains of the same 
isotype (CH domains). The variable region consists of the VL and VH domains. The constant region 
is made up of the CL and CH regions (Brekke et al. 1995).  
 
Figure 1.3 – The structure of a basic PP-I polyproline-α helix. The polyproline helices found within the 
hinge region of immunoglobulins give the region its characteristic flexibility. The Ig helices contain cysteine 
residues which have been found to produce intra-chain disulfide bonds, which are responsible for providing 
rigidity to the hinge region. Model produced in coot.   
The two paired heavy chains within this region interact with effector molecules such as C1q, any 
functional differences between the different isotypes are primarily due to differences in the Fc region. 
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The receptors found on T cells and B cells are called Fcγ receptors. One of these receptors is the 
FcγRIIB-1 located on B cells (Schur, 1988). 
All of the domains within IgG display immunoglobulin folds, which are made up of a pair of anti-
parallel β sheets surrounding a hydrophobic core and linked by a single intra-chain disulfide bond. 
The second key feature of this fold is the hypervariable loops found at its N-terminus which form a 
binding surface. The loops in the folds of the constant regions are not variable, instead these loops 
are universal across all antibodies. It is the hypervariable loops which contain the complementary 
determining regions of the antibody and give rise to the vast diversity seen within the antibody 
subclasses (Janeway et al., 2001). The structure of the immunoglobulin fold is shown in figure 1.4. 
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Figure 1.4 – A diagram of the immunoglobulin fold. The immunoglobulin fold is one of the most prevalent 
protein folds found within the human genome whose hypervariable loops are responsible for the vast diversity 
within each of antibodies. The anti-parallel β-sheet is shown, the α helix is shown in red and the linking regions 
are shown in grey. The 3 bond “β” turns are shown in pink and the 5 bond “π” turns are shown in orange. 
Produced in CCP4mg. 
The domains within the Fc region are universally conserved, being 90% homologous between IgG 
isotypes and are all on average 110 amino acids in length. Structural studies performed on the Fc 
region have revealed that the two CH2 domains have no protein-protein contacts with each other and 
so only interact through their N-linked glycans either through direct hydrogen bonds or through 
hydrogen bonds formed using water as an intermediate. The CH3 regions do however have direct 
interactions due to the fact that they are closely packed together within the structure, these 
interactions form the base for the heavy chain dimer. These studies have also shown that the Asn297 
N-linked carbohydrate is universally conserved in all IgG isotypes as well as in the CH2 domains of 
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IgM, IgD and IgE. The Asn297 residue is located on a loop that links the C and E chains (C’E loop). 
This glycan is important to the function of IgG because alteration to it causes modulation of the 
function of IgG and binding affinity (Prabakaran et al., 2008).  
1.1.4  IgG Fc– Glycosylation 
Natural glycosylation levels of IgG Fc have been found to be a reflection of the physiological 
conditions within an organism and therefore any changes within said organism (Wuhrer et al., 2009). 
There are several glycans bound to IgG, with the most important being located in the Fc region. 
These glycans are N-linked to the universally conserved Asn297 residue located within the first half 
of the CH2 domains (Sondermann et al., 2000). Through manipulation of these glycans it is possible 
to mediate the receptor affinity of IgG as well as its activity through their participation in Fcγ receptor 
binding (Sondermann et al., 2000). 
These glycans are classified as “complex glycans” due to them containing some of the more rarely 
seen glycosidic linkages such as: β1,2 linkages and α1,3 linkages. The main structure of the glycan 
is that of a core heptosaccharide which contains four N-acetylglucosamine (GlcNac) residues. One 
of these GlcNAc residues (GlcNAc1) is bound directly to Asn297 and forms an α1,6 linkage with a 
fucose residue and three Mannoses which form the start of two separate arms. These arms can then 
be extended through the addition of two galactose residues and further again by two sialic acid 
residues (Krapp et al., 2003; Zauner et al., 2013). The structure of the glycans is shown in figure 1.5.  
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Figure 1.5 – The N-linked carbohydrate attached to the Fc region of IgG at residue Asn297.  The core 
heptasaccharide is shown highlighted in grey. The numbers above and below the residues indicate the type of 
linkage between them. The bisecting GlcNAc* attached at Man4 only occurs in 5-10% of naturally occurring 
IgGs (Krapp et al., 2003). 
Structural studies of the oligosaccharide have determined that the moiety branches into two arms at 
the Man3 residue; the first of these arms, the α(1-6) arm is directed towards the CH2-CH3 interface 
and makes several interactions with the CH2 domain through multiple non-covalent interactions with 
hydrophobic residues (Kiyoshi et al. 2017). The α(1-3) arm extends into the space between the two 
CH2 domains and forms a crosslink with the α(1-3) arm of the glycan associated with the other chain 
(Arnold et al. 2007). Complete deglycosylation of the Fc region results in IgG Fc losing its ability 
to bind to FcγRs, due to the two chains of the Fc region moving closer together effectively restricting 
access to the binding site, this causes  IgG to fail to initiate the correct effector functions (Subedi et 
al. 2014; Barb 2015; Subedi et al 2015). The binding affinity of truncated glycoforms of IgG was 
tested and demonstrated a progressive decrease in FcγRIIb binding affinity with progressive 
reduction in glycan size again caused by the restriction of the binding site (Mimura et al. 2000). 
Whilst the biological effects of these different residues have been observed and documented, the 
specific manner in which these oligosaccharides influence the structure of the Fc region and function 
remains unclear (Wright et al. 1991). A lack of fucose, galactose and sialic acid bound to the Asp297 
core N-glycan, increases the ability of IgG2 to induce antibody-dependent cell-mediated cytotoxicity 
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(ADCC) in mice (Quast et al. 2017). Deglycosylation is also associated with various diseases such 
as autoimmune diseases, which are associated with a reduction in galactosylation and sialylation of 
the Fc IgG region which is also a hallmark of the inflammation associated with these diseases. 
Different cancers as well as viral infections have been shown to exhibit similar low galactosylation 
and sialylation of the Fc N-glycans in mild inflammatory conditions (Quast et al. 2017). It has been 
proposed that low levels of galactosylation and sialylation is a biomarker of chronic weak 
inflammation in elderly patients and more generally as a marker of immune activation (Quast et al. 
2017 & Bondt et al. 2013).  
As the level glycosylation of IgG Fc is known to be altered during inflammation, several cases of 
the association of C-reactive protein (CRP) with several of the IgG glycoforms have been reported. 
It is also unsurprising because both CRP and IgG are associated with inflammation and 
cardiovascular diseases however there is a lack of recorded associations between glycosylation and 
the assorted clinical markers in the metabolic health of healthy people (Dube et al. 1990). One of 
these studies found that all non-galactosylated glycoforms of IgG were positively associated with 
CRP levels and di-galactosylated glycoforms were negatively associated with CRP levels. It was 
also found that upon the addition of CRP the half-life of the IgG antibodies was significantly 
increased. The different IgG subclasses show differing levels of glycosylation; with IgG2 showing 
higher levels of fucosylation and lower levels of bisection and galactosylation compared to other 
subclasses; the galactosylation and sialylation of IgG causes the IgG to display a weaker affinity for 
inflammation markers compared to IgG1 and IgG4 glycoforms. This corroborates the data found in 
other literature which indicated that IgG2 has the lowest affinity for FcγRs as well as having the 
lowest ADCC activity (Plomp et al. 2017). This lower association can be explained by the production 
of IgG2 being primarily triggered during T-cell independent immune reactions. All of this data points 
towards IgG2 having a much more limited role in the inflammatory response than other subtypes 
(Plomp et al. 2017). Due to the large potential library of these antibody glycoforms a large catalogue 
of antibody therapeutics is being developed. Their usefulness will be determined by their affinities 
to their various receptors as well as their specificity for their designated antigens. These treatments 
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may revolve around upregulation or downregulation of effector function depending on the treatment. 
Since FcγRIII is dependent on IgG glycosylation the oligosaccharide moiety must exert an influence 
on the conformation of the Fc fragment of IgG; it is therefore important to fully understand just how 
differential glycosylation affects IgG. 
1.1.5  The Effector Mechanisms of IgG-Fc 
Antibodies link the adaptive immune response to the innate immune system through effector 
mechanisms such as C1q proteins, they do this by combining antigen-binding sites with innate 
immune receptors. The different subclasses have different affinities for the effectors as well as 
differing levels of action, for example IgG1 and IgG3 are more potent activators than IgG2 and IgG4 
both of which have more subtle levels of action (Bruhns et al. 2009). Binding to the C1q proteins 
causes the activation of the complement cascade through the classical pathway (IgG complement 
activation via the alternative pathway has not been observed). The interaction between C1q and IgG 
Fc occurs via the globular heads of C1q interacting with residues 285-292 and 317-340 of the heavy 
chain of CH2. The binding affinity of C1q for IgGs is dependent on the level of steric interference 
caused by the FAB arms as the C1q protein approaches the CH2 sites: IgG3>IgG1>IgG2>IgG4. 
Generally it has been observed that IgG4 does not interact with C1q and in fact appears to inhibit 
immune precipitation as well as the binding of C1q to IgG1 in mixtures of IgG4 and IgG1. It is 
therefore thought that IgG4 may be protective against the effects of the complement-fixing 
antibodies.  
1.1.6  Structural Studies of Fcγ Receptors 
The second effector mechanism of the IgG subclasses is the ability to interact with the cell surface 
Fc receptors. The Fc receptors that are specific to IgGs are referred to as FcγRs, with these 
structurally distinct receptors being differentiated by the superseding roman numerals (Ravetch & 
Lanier 2000). After they have been activated by antigens on the surface of certain cell types (usually 
pathogenic cells), the IgG subclasses can interact with these Fc receptors to facilitate the clearance 
of these cells through phagocytosis (Nimmerjahn & Revetch 2006). There are three classes of human 
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IgG Fc receptors on leukocytes: FcγRI, FcγRII and FcγRIII. These receptors are differentiated by 
their structures, cellular presence and their subclass affinities (Ravetch & Lanier 2000). The cellular 
expression of the receptors are as follows: FcγRI on monocytes; FcγRII on monocytes, neutrophils, 
eosinophils, platelets, and B cells and FcγRIII on neutrophils, eosinophils, macrophages, and natural 
killer cells. The FcR family of proteins are all a part of the type I transmembrane glycoprotein 
superfamily except for FcγRIIIB which is GPI anchored (Nimmerjahn & Revetch 2006). Whilst 
FcγRs primarily bind IgG they have also been known to bind pentraxins such as C-reactive protein, 
serum amyloid P and other innate immune proteins. However, the full importance of these 
interactions is as of yet unknown (Vidarsson et al. 2014).  
1.1.7  FcγR mechanism of action 
Over 100 residues in the Fc region have been found to be associated with FcγR binding to IgG1. In 
the first of these regions located in the lower hinge the Leu234 and Leu235 residues are thought to 
be critical to the binding process as a substitution of even one of these residues results in an affinity 
reduction of 10-100 fold (Ravetch 2003). The second region is located in the bend between two of 
the β strands in the CH2 domain and contributes a Pro331 residue to the binding pocket. Because of 
how the β strands fold during synthesis this residue is 11 A
ͦ
 from the hinge linker region and 
substitution of this residue results in an affinity reduction of Fc receptor constant by 1- fold. (Ravetch 
2003), the FcγR binding pocket is shown in figure 1.6. 
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Figure 1.6 – The structure of the Fcγ receptor binding pocket. The binding pocket is located within the 
lower region of the hinge as well as the start of the CH2 domains of the Fc region of IgG, there is some 
variation within this binding pocket between the IgG subtypes as well as between the different Ig families 
(figures taken from Kiyoshi et al 2015). A. The structure of the IgG-Fc/ FcγR complex with the two binding 
pockets highlighted in boxes. B. Subsite 1, located on the A chain in the region between the CH2 and CH3 
domains. C. Subsite 2, located on the B chain in the region between the CH2 and CH3 domains. 
1.1.8  FcγRn 
FcRns mediate the transport of maternal IgGs across the placenta to the child during pregnancy; 
transferring humoral immunity to the foetus/ child against antigens that the mother has already 
encountered. Its secondary function is to protect IgG from degradation.  FcRns achieve this by acting 
as a receptor which is responsible for maintaining the long half-life of IgG as well as maintaining  
high concentrations of IgG in serum (Ghetie & Ward 2000). The Ile253 and His310 residues in 
between the CH2 and CH3 domains have been shown to be the key players in the interaction between 
FcRn and IgG Fc; these residues have been shown to be highly conserved across species (Martin et 
al. 2001). Structural studies in mice have shown that a mutation of the His433 residue to an alanine 
residue does not affect its activity levels however simultaneous mutation of both the His433 and 
Asn434 moderately reduces it (Kim et al. 1999). These studies have also shown that mutation of the 
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His435 to an alanine dramatically reduces the activity levels (Martin & Bjorkman 1999).  Spatial 
studies have implied that the sequential differences at residue 435 in IgG1 and IgG3 (His in IgG1 
and Arg in IgG3) is responsible for IgG3s reduced activity during FcRn/Fc interactions which has 
provided a greater level of evidence to support the importance of residue 435 in FcRn binding (Kim 
et al. 1999). There is however a discrepancy in this theory as studies performed using surface 
plasmon resonance analysis of a chimeric mouse/human IgG1 detected no significant difference in 
the pH dependence of the FcRn-IgG1 interaction when the His435 was mutated to an arginine 
(Medesan et al. 1997). Other results found in this study implied that it was in fact the His433 residue 
which has a role in FcRn binding. This discrepancy in the data is most likely due to the different 
methods used, however the data from both techniques prove that histidine residues are heavily 
involved in FcRn binding. The role of histidine in FcRn binding helps to explain the strict pH 
dependence of the interaction (Ghetie & Ward 2000). More recent studies have shown that the 
His310 and His435 residues become protonated between pH 6.0 and 6.5 and it is once they have 
become protonated that they form salt bridges with the anionic Glu117, Glu132 and/or Glu135 and 
Asp137 residues on the α2 -helix of FcRn. 
1.2  Structural Studies of IgG 
1.2.1  IgG-Fc bound to FcγRI 
FcγRI is one of the major receptors found on the surface membranes of immune cells, specifically: 
macrophages, neutrophils and dendritic cells. Several studies have linked the FcγRI to several roles 
within the immune system. Despite the fact FcγRI has the highest affinity interaction of the Fc 
region; the structure of IgG Fc bound to FcγRI has only been recently reported. A study performed 
in 2015 was the first to report a high resolution (1.80 A
ͦ
) structure of the interaction site of the FcγRI: 
Fc interaction. The x-ray crystallographic data reports that the majority of the interactions between 
the FcγRI binding subsite 1 and the Fc fragment involve the Pro232 – Ser239 residues of the lower 
hinge region of the CH2 domain. A number of conformational changes which occur during this 
interaction were also reported in this study, the most notable of which is the rigid-body displacement 
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of the D3 domain of the FcγRI, this displacement is 11 A
ͦ
 in magnitude with a rotation element of 
19° in relation to the D1 and D2 domains (also of FcγRI). This displacement occurs away from the 
main binding sites and as such it is unknown whether this movement has an effect on the binding 
interaction or whether it is just a by-product of it (Kiyoshi et al. 2015). 
 
Figure 1.7 – The structure of the human IgG1 Fc region bound to the human FcγRI receptor. The 
electron density map is shown in grey. The Fc region is depicted in yellow, the FcγRI receptor is shown in 
blue and the glycosylation of both proteins is shown in green (Kiyoshi et al. 2015 supplementary material).  
Through comparison of 1.80 A
ͦ
 structure of bound Fc/ FcγRI to the structure of Fc it was shown that 
the only change experienced by the Fc fragment is a rigid body displacement within the CH2 
domains. This displacement takes the form of a pair of asymmetrical rotations within the A and B 
chains, with the rotation in the B chain being 10.7° with respect to the CH3 domain and a much 
smaller rotation in the A chain (amplitude of rotation 2 A
ͦ
). The result of this shift was a 9 A
ͦ
 increase 
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in the distance between the two CH2 domains by the hinge region. There were also several features 
observed in FcγRI bound Fc that were not present in the structures of native Fc or Fc bound to other 
Fcγ receptors. The most important difference is that the Leu235 residue of the A chains CH2 domain 
is located within a hydrophobic pocket within the FcγR, mutational studies have implied that this 
Leu residue is critical to the high affinity binding of the Fc region to this receptor. This is backed up 
by the fact that it has been observed that the buried surface area of this residue accounts for 25% of 
the A chains interaction with the Fc region. This also helps to explain why the IgG2/FcγRI interaction 
has such a low affinity, this is due to the fact that residue 235 in IgG2-Fc is not a leucine residue and 
as such cannot adequately interact with the hydrophobic pocket (Kiyoshi et al. 2015). 
  
Figure 1.8 – The electron density of the hydrophobic binding pocket of the IgG1 Fc: fcγRI interaction, 
showing both subsites. The surface of fcγRI is represented by the cyan surface diagram. The electron density 
map for the A chain of the fc region is projected onto the sequence of residues 232-237 for subsite 1 and for 
residues 235-238 for subsite 2 (Kiyoshi et al. 2015 supplementary material). 
1.2.2  Modification of the N-Linked Glycan 
1.2.2.1  Afucosylated IgG1-Fc 
It has recently been observed that the afucosylation of the N-linked glycan of the Fc region improves 
the antibody-dependant cellular cytotoxicity (ADCC) as shown by a 50-fold increase in the binding 
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affinity of FcγRIIIa. X-ray crystallographic analysis of the KM3060 (chimeric anti-CCR4) and 
KM3575 (chimeric anti-CD20) antibodies, which acted as the fucosylated and afucosylated 
antibodies respectively; determined that the removal of the fucose residue only produced a very 
subtle change within the secondary structure of the Fc region (RMS deviation of 0.32 A
ͦ
). These 
antibodies were chosen due to their identical Fc region residue sequences. The structural analysis 
also determined that upon binding to FcγRIIIa there is a conformational change within the C’/E loop 
of the Fc specifically around residue Tyr296 which has been shown to have interactions with both 
Lys125 and Asp126 of FcγRIIIa. 1H NMR data of the area around Tyr296 indicated that there was a 
very minute shift in the placement of Tyr296 within the afucosylated Fc region possibly due to the 
differing hydrogen bond profile when fucose is removed. The effect of this shift is that Tyr296 is 
more flexible within the afucosylated Fc and hence more readily binds and adjusts to FcγRIIIa. 
Another potential explanation for the increased affinity is, that the carbohydrate attached at Asn162 
on FcγRIIIa can only interact with the surface of the Fc region when fucose is not present (Ferrara 
et al. 2006). 
1.2.2.2  Sialylated IgG-Fc  
A study by Crispin et al `used in-vitro enriched sialylated 2,6-Fc fragments (sFc) of IgG which were 
derived from IgG-Fc obtained from sera. The sialic acid residues were found bound to the galactose 
saccharide of the 1,6 arm of the biantennary N-linked glycans. Initial testing found that these Fc 
fragments bound to the SIGN-R1 and DC-SIGN c-type lectins whereas native IgGs would not. The 
sFc was also found to have a 10 fold lower affinity for FcγRIIb receptor. The reason for this new 
binding mechanism was first thought to be due to the 2,6-Sialic acid galactose bonds causing the Fc 
fragment to adopt a new conformation which allows it to bind to SIGN and DC-SIGN. However a 
follow up study in 2013 demonstrated using X-ray crystallography as well as CD that the structure 
of the sFc was typical of a native Fc region and so the mechanism of binding is uncertain at this time. 
This interaction is still very important however as it is the first documented case of the Fc region 
gaining a binding mechanism through manipulation of the N-linked glycan and has opened up the 
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idea that manipulation of the glycan in other ways could lead to IgG gaining other new binding 
mechanisms (Crispin et al. 2013).  
 
Figure 1.9 – The structure of human IgG Fc whose N-linked glycan is enriched at α2,6-sialic acid residue. 
The CH2 domains are shown in blue and the CH3 domains are shown in orange PDB code 4BYH (Crispin et 
al. 2013).  
1.2.2.3  Mutant IgG Fc-Fragments 
There have been many studies into the alteration of the Fc region through residue mutations in order 
to enhance or supress the binding activity of Fc to FcγRs. One study demonstrates the binding affinity 
for FcγRIIIa of the SDIE (S239D/I332E mutations) and the SDALIE (S239D/A330L/I332E 
mutations) Fc mutants. In this study these mutants showed a 60-fold and 170-fold increase in binding 
affinity for FcγRIIIa respectively. A separate study showed that they also had a 70-fold and 40-fold 
increase in affinity respectively (Lazar et al. 2006). The crystal structure of SDALIE produced in 
2008 (Oganesyan et al. 2008) displayed that the Fc region is very structurally similar to the many 
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reported wild-type Fc fragments with the root mean square deviations being no greater than 0.6 A
ͦ
 
for the main chain atoms. However these studies also showed that these mutant type Fc regions have 
a more open conformation but without any differences in the FcγR binding domain. Another feature 
of the structures of these mutants is that when their CH2 and CH3 domains are considered 
individually they show a considerable level of conservation, but with a considerable level of 
flexibility within the domains (Oganesyan et al. 2008).  
 
Figure 1.10 – The structures present within the asymmetric unit of the SDALIE crystal. The three 
mutations are shown in red with the N-linked glycan being shown as in the stick representation (Oganesyan et 
al. 2008).  
Further studies into these mutated Fc fragments have revealed that the GASDALIE mutant which 
contained the G236A/S239D/A330L/I332E mutation pattern showed a 20 – 30 fold greater affinity 
for activating FcγRIIIa, with a much smaller increase in affinity for FcγRIIb (2 – 3 fold increase). 
The implication of which, is that GASDALIE acts as an activator rather than an inhibitor. Recent 
studies using a mouse model have shown that GASDALIE antibodies have protective properties 
against certain cancers and other infectious diseases such as HIV (Ahmed et al. 2016).  
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Figure 1.11 – The structure of the GASDALIE Fc region bound to FcγRIIIa. FcγRIIIa is depicted as the 
purple ribbon and GASDALIE is depicted as the blue ribbon. The 4 mutated residues are shown as red spheres 
and the N-linked glycan is depicted as a blue stick model PDB code 5D6D (Ahmed et al. 2016).  
The mutant-Fc structure was solved through molecular replacement using the afucosylated Fc: FcγR 
structure as a search model before being refined to 3.1 A
ͦ
. The electron density map clearly showed 
the position of the sites of the GASDALIE substitutions (position 236, 239, 330 and 332) on the A 
and B chain.  The crystal structure of the mutant-Fcs showed that it had the same asymmetric 1:1 
interaction with the FcγR D loops that is seen in the other IgG Fc fragments and that the dfferent 
mutations altered the structure and binding affinity in comparison to native Fc. The GASDALIE 
specific interactions of the A chain are as follows: the lys120 residue of the BC loop in FcγRIIIa was 
found to be positioned in-between the Asp239 and Asp265 residues, which is vastly different to the 
native interaction which sees the Ser239 residue forming a hydrogen bond with the lys120 residue. 
The AL and IE substitution were found have no effect on the interaction of the A chain with FcγRIIIa. 
Whilst the GA substitution of the GASDALIE Fc was also found to have no effect on the interaction, 
the Gly236 of the native Fc formed a hydrogen bond with the His135 residue within the FcγR. It is 
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thought that the increase in binding affinity in the GASDALIE Fc was due to the introduction of the 
salt bridge at position 239 due to the fact that a singular salt bridge is much stronger than the two 
hydrogen bonds which are lost due to the mutation. The B chain shows new interactions formed due 
to the introduction of the GASDALIE mutations and they are as follows: the IE substitution on the 
B chain formed an electrostatic interaction with Lys161. This interaction is not seen in the native Fc 
as the Ile332 cannot form an interaction with the lys161. The GA substitution makes a new 
hydrophobic interaction with the Phe158 residue of the FcγRIIIa, which differs to the native Fc as 
residue 158 is not contacted and Gly236 forms a hydrogen bond with Lys161 of FcγRIIIa. The other 
two mutations on the B chain were not found on the binding interface and as such had no effect on 
the affinity of the interaction. It is the new salt bridge and hydrophobic interactions that are thought 
to be responsible for contributing to the increase in affinity (Ahmed et al. 2016). 
1.2.3  Applications of IgG-Fc in Combating the Zika Virus 
The Zika virus (ZIKV), a member of the Flaviviridea family of viruses is the causative agent of the 
infection caused by bites from the Aedes aegypti species of mosquitoes, it was first identified in the 
Zika forest of Uganda in 1947 (Dick 1952). As of yet the full implications of this infection for human 
health is unknown, however some symptoms, such as serious birth defects (which include 
neurological disorders and microcephaly) have been reported in several studies focused around 
Brazil (Cugola et al. 2016). The flavivirus family is characterised by their envelope protein (ZIKV 
E). The ZIKV E protein is a single polypeptide that is processed into 3 mature structural, viral 
proteins including: a pre-membrane protein, a non-structural protein and an envelope glycoprotein. 
Studies of the ZIKV E have shown that it is split into three domains: DI, DII and DIII all folded into 
an elongated rod like structure which sits horizontal to the envelope forming antiparallel dimers. The 
DII is formed by an elongated finger like structure which contains a hydrophobic glycine rich fusion 
loop (E fusion protein) at its most distal loop. This fusion protein consists of residues 98-110 and is 
responsible for interacting with target cell membranes during cell fusion, it does this by inserting 
itself into the targets membrane during the pH-dependent conformational changes that occur during 
fusion (Dai et al. 2016). It is this fusion protein that is of particular interest to researchers due to the 
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fact that it is highly conserved in the flavivirus family and as such it is a tempting target for 
monoclonal antibodies (Mabs). To this end several mabs were tested in mice models and two in 
particular (ZV-54 and ZZ-67) were found to have a neutralising effect on ZIKV activity (Zhao et al. 
2016). To date only one effective human anti-flavivirus mab has been produced; designated 2A10G6 
it is a monoclonal IgG1 antibody that has been shown to be effective against type 1-4 Dengue 
(DENV1-4), Yellow Fever virus and West Nile virus. The method of action for 2A10G6 has been 
detailed through X-ray crystallographic studies, which showed that the Fab region of 2A10G6 binds 
to the tip of the ZIKV-E domain in a perpendicular manner which in turn embeds the fusion loop in 
a hydrophobic pocket formed by the heavy and light chains of the antibody as well as the W101, 
L107 and F108 residues of the ZIKV-E. These residues are highly conserved in the flavivirus family 
hence 2A10G6s broad capacity (Deng et al. 2011). 
 
Figure 1.12 – The structure of the 2A10G6s antibody in bound to three different flavivirus E proteins, 
The DENV2, West Nile Virus (WNV) and Tick-borne encephalitis virus (TBEV) are shown in red, blue and 
cyan respectively. The three key residues which are involved with the binding of the flavivirus E fusion protein 
are also labelled within this structure (Deng et al. 2011).   
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1.3  An Introduction to Heparin & Heparan Sulfates 
1.3.1  Heparin & Heparan Sulfates 
Heparin is a linear polysaccharide which is a part of the Heparan Sulfate (HS) family of 
glycosaminoglycans (GAGs). The structure of Heparin is made up of uronic acid (1-4) -D-
glucosamine repeating disaccharide subunits the structures of which are shown in figure 1.13. 
Heparin contains variable random patterns of substitution of these disaccharide subunits with N-
sulfate, O-sulfate and N-acetyl groups, this substitution gives rise to a random and variable pattern 
of sulfation within heparin molecules, as well as a large number of complex members of the GAG 
polysaccharide family (Robinson et al. 1978). 
 
Figure 1.13. (a) The structures of the base monosaccharide units of heparin. (b) The structures of the 
major and minor repeating disaccharide subunits of heparin. Produced in Chemdraw.  
Major repeating unit 
Minor repeating unit 
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Heparin is expressed in mast cells found in connective tissues where it is synthesised as heparin 
proteoglycan (75 KDa - 100 KDa) (Conrad 1998). This proteoglycan consists of a unique core 
protein (serglycin) and polysaccharide chains that are covalently bonded to it. Once synthesis is 
complete these chains are cleaved at random intervals in order to give rise to a large amount of 
smaller polydiverse heparin chains, these are then stored in the secretory granules of mast cells as 
complexes with proteases. Because heparin is produced in mast cells it is sparser within the body 
than HS due to the fact that mast cells are found in organs that are commonly exposed to pathogens 
such as the liver and the lungs and HS is found in tissues throughout the body (Salmavirta et al 
1996). Another feature of heparin is the differing structures and sulfation patterns of heparins 
produced in different tissues. An example of this is pig intestine heparin which contains an ATIII 
binding site that contains N -acetyl D-glucosamine and cow lung heparin which contains N-sulfo D-
glucosamine; these differences account for their different binding affinity. Commercial heparin was 
initially sourced from dog liver, Charles Best began a project to first produce bovine lung heparin 
and then porcine intestine heparin (Rabenstein 2002). All of the disaccharide structures found within 
heparin are also found within heparan sulfate but in different proportions, this helps to explain why 
the level of sulfation is different between the two GAGs. It also explains why their anticoagulant 
activity is different between the two (Rabenstein 2002).  
1.3.2  Structural Details of Heparin and Heparan Sulfate 
The main constituent of heparin and HS is an α1-4 linked pyranosyl uronic acid (uronic acid) and 2-
amino-2-deoxyglucopyranose (D-glucosamine) repeating disaccharide unit.  The uronic acid subunit 
ratio is 90% L-iduronic acid and 10% D-glucuronic acid. Heparin has the highest negative charge of 
all biological molecules making it a polyelectrolyte. There are several differences at the disaccharide 
levels between different forms of heparin (sequence microheterogeneity); heparin is also 
polydisperse with a molecular weight range of 5-40 kDa with an average of 12 kDa and an average 
negative charge of 75 making characterisation difficult. D-glucuronic acid makes up the majority of 
the structure of heparan sulfate which is polydisperse; with a molecular weight ranging from 5-50 
kDa and an average of 30 kDa. Whilst the main chain structure of HS has reduced sulfation (by 
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comparison to heparin), the sulfation is more uniform and organised, with several of the domains 
contain defined extended sequences of sulfation; either being highly sulfated or less sulfated; HS 
also remains connected to its core protein unlike heparin. There are two types of HS proteoglycans 
which are found on the extracellular matrix and the cell surface; these two proteoglycans are 
syndecans and glypicans. The HS chains associated with these proteoglycans are responsible for 
mediating physiologically important processes. Heparin and HS can be distinguished by their 
differing affinities to the GAG degrading enzymes: heparin lyases. Neither one of them has a tertiary 
structure instead existing as extended ɑ-helices; this structure plays an important role in the 
specificity of their interactions with proteins as these interactions depend on how the sulfo and 
carboxyl groups are displayed on its surface. The large range of interactions attributed to this family 
of GAGs is believed to be due to the flexibility of the L-iduronic acid residues within the GAGs. 
The level and type of flexibility depends on the position of these residues within the chain. Heparin 
exists largely as a linear right handed helix however they do not contain any tertiary folds or 
structures (Rabenstein 2002).   
Complete structural analysis of the structure of heparin would require the identification and 
quantification of each of the uronic acid-(1,4)-glucosamine disaccharides as well as the 
determination of their sequence within the polysaccharide chain. It would also require the 
characterisation of the 3D structures of the monosaccharide residues, which is incredibly difficult 
due to their highly poly-diverse natures. Because of this the actual structure of heparin is unknown 
(Rabenstein 2002). Whilst the overall structure is unknown the disaccharide compositions of the 
different heparin preparations can be determined through analysis of the products formed by the 
exhaustive cleavage of heparin through deamination or enzymatic cleavage of the uronic acid-(1,4)-
glucosamine glycosidic bonds. Of the 48 known disaccharides only 19 have been observed in 
heparin. Deaminative hydrolysis using nitrous acid gives selective and quantitative cleavage of the 
glycosidic bonds of the N-sulfated GlcN residues whilst retaining the O-sulfated substituents as well 
as the isomeric features of the uronic acid residues (Conrad 1998). The GlcNS, GlcNS(6S), 
GlcNS(3S) residues are converted to the following 2,5-anhydro-D-mannose (AM) residues: AM, 
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AM(6S), AM(3S) and AM(3,6S). Because the bonds of N-acetylated GlcN residues are not cleaved; 
the products of deamination are disaccharides, as well as tetrasaccharides. These polysaccharides 
contain an internal GlcNAc residue. The most common of these products is IdoA(2S)-(1,4)-AM(6S); 
which is formed from IdoA(2S)-(1,4)-GlcNS(6S), the most common disaccharide in heparin 
(Bienkowski & Conrad 1985). The N-acetylated glcN glycosidic bonds can be cleaved by removing 
the acetyl group through a reaction with hydrazine and then cleaving the glycosidic bonds through 
deamination at pH 4.0 which is much higher than the pH of 1.5 required for deamination of the 
glycosidic bonds of the N-sulfated GlcN residues. The AM residues can be radiolabelled using 
NaB3H4, which enables detection of the oligosaccharides after separation by gel permeation 
chromatography or strong anion exchange (SAX)-HPLC (Loganathan et al. 1990). The heparinase 
class of enzymes are obtained from Flavobacterium heparinum and cleave the uronic acid-(1,4)-
glucosamine glycosidic bonds leaving the glucosamine residue and the sulfated substituents intact 
but cause it to produce a terminal uronate with an unsaturated 4,5 carbon bond (ΔUA) at the 
nonreducing end. Due to both IdoA and GlcA residues being converted into terminal ΔUA any 
information about the conformation of the uronic acid is lost.  Heparinase I has high specificity for 
IdoA(2S) glycosidic bonds where the glucosamine can be GlcNS, GlcNS(6S) or GlcNS(3S) and a 
secondary specificity to GlcA(2S) bonds in highly sulfated regions (Conrad 1998; Venkataraman et 
al. 1999). Heparinase II is less specific in that it will cleave glycosidic linkages that contain both 2-
O-sulfated and 2-OH uronic acids. Heparinase III has high specificity for 2-OH GlcA-containing 
glycosidic linkages and to a lesser extent 2-OH IdoA-containing linkages in unsulfated regions of 
heparin. The ΔUA double bond is a chromophore and is a convenient method of monitoring the 
progress of depolymerisation and as a way to detect the oligosaccharides which are separated by 
SAX-HPLC and capillary electrophoresis (CE). The disaccharides which are produced by this 
cleavage can be identified by comparing their retention times with those of the ΔUA containing 
disaccharide strands. The partial cleavage of heparin using nitrous acid and the heparinases is widely 
used to produce tetra, hexa, and higher oligosaccharides to allow for further study. Chemically 
discrete oligosaccharides can be isolated from the cleavage mixtures through a two-step separation 
procedure which involves size separation into small oligosaccharide fractions via gel permeation 
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chromatography and then separation based on charge through SAX-HPLC (Venkataraman et al. 
1999). Each of these fractions will contain many separate components often there are more than 40 
discrete components. Because of this only small quantities of each discrete oligosaccharide can be 
produced by heparinase depolymerisation (Rabenstein 2002).   
The final structure of heparin is a product of incomplete biosynthetic modification of its precursors. 
This modification is mediated by substrate specificities of the modification enzymes as well as 
cellular regulation. The biosynthesis of the chains takes place in three stages; the first of which is 
chain initiation which involves the stepwise addition of a xylose residue, two galactose residues and 
a GlcA residue to specific serine residues at intervals along the chain. This produces the 𝛽-GlcA-
(1,3)-𝛽-Gla-(1,3)-𝛽-Gal-(1,3)-𝛽-Xyl- tetrasaccharide linker. The heparin chains are then constructed 
by the alternating addition of 1-4 linked GlcNAc and GlcA units to the linker; this forms [GlcA-
(1,4)-GlcNAc]n polymer chains, these chains are then modified further through N-deacetylase/ 
sulfotransferase, epimerase and O-sulfotransferase catalysed reactions. These reactions occur in a 
specific order and the products of the reactions are used in the next ones, this produces the mature 
heparin. The reactions are referred to as incomplete as not all of the sites available in these reactions 
are used as a result the complexity of the final product is increased throughout the process 
(Rabenstein 2002).  
1.3.3  The Structural Differences of Heparan Sulfate 
HS is also synthesised as a proteoglycan, but unlike heparin it is produced and secreted by all 
mammalian cells. The proteoglycans associated with the structure of HS are shorter and are made 
up of fewer polysaccharide chains. The expression of the HS proteoglycan is tissue specific and can 
change during synthesis. Much like in heparin this differential expression is because of the activation 
tissue specific enzymes which are involved in the synthesis process; the most common tissue specific 
difference is the variability in chain length and sulfation patterns. Another example of the differences 
between heparin and HS is that the overall molecular organisation of HS remains the same during 
the progression of colon cells towards malignancy, however the levels of sulfation in the N-sulfated 
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(NS) domains and N-acetylated/N-sulfated (NA/NS) regions changes. It has also been noted that 
changes in the patterns of 6-O-sulfation, chain length and the number of sulfated domains with HS 
produced by neuronal cells occur alongside the transition from neural precursor cells to neuronal 
differentiation. (Venkataraman et al. 1999). 
There are two subfamilies of the cell surface HS proteoglycans: the syndecans (four members) and 
the glypicans (six members) the amino acid sequences of their core proteins and the mode of 
interaction with cell membranes differ between the two subfamilies. The syndecans core protein is 
a transmembrane protein, whilst the glypicans protein is an extracellular membrane protein bound 
via a glycosylphosphatidylinositol tail. As such the two types of HS glycoproteins found in the 
extracellular matrix can be distinguished by their unique core proteins. The HS polysaccharide 
chains are bound to the core proteins via the same tetrasaccharide linkers found in heparin 
proteoglycans. The biosynthesis pathways consist of the same synthesis/ modification pathways as 
the heparin reactions, however the modification of the [GlcA-(1,4)-GlcNAc]n polymer chains is 
more localised than in heparin; The chains also contain more GlcNAc residues and the GlcNS to 
GlcNAc ratio is 1:1 in HS but is 4:1 in heparin. The GlcNAc disaccharides primarily occur in the 
unmodified NA domains and the GlcNS occur in the NS domains where there are mixed sequences 
of N-acetyl and N-sulfated separate the two types of domains. The mixture of the two sequences 
may be significant, the primary evidence of this is the antithrombin-binding domain which contains 
a mixture of GlcNAc and GlcNS residues and GlcA and IdoA residues (Rabenstein 2002).  
HS also has fewer O-sulfate groups than heparin and the number is far more variable, the range is 
0.2-0.7 sulfates per disaccharide as compared to an average of 2.4 sulfates per disaccharide in 
heparin. There are four isoforms of N-deacetylase/ N-sulfotransferases, three isoforms of 6-O-
sulfotransferase and five isoforms of 3-O-sulfotransferases that are known; each of which have 
distinct substrate recognition properties. Only single isoforms of the 2-O-sulfotransferases and C5 
epimerase have been identified. There is evidence to suggest that each of these isoforms act on a 
different precursor sequence and produce different final structures. These reactions occur in the NS, 
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NA and the NA/NS domains, the structures of which are shown in figure 1.14. Most of the uronate 
residues are converted to IdoA, which is often then 2-O-sulfonated, thus IdoA is the major repeating 
disaccharide of the NS domain with its variable levels of sulfonation. The primary structure of HS 
is tissue specific and can be different for every cell within the same tissue.  There is also evidence 
for regulated expression of specific domains in the HS chains however the mechanism of this 
regulation is unknown (Rabenstein 2002; Salmavirta et al 1996). 
 
Figure 1.14. (a) An illustration of the sulfation and acetyl domains within the structure of HS. The N-
acetylated residues are shown colourless shapes and the N-sulfated residues are shown as solid shapes. GlcNS 
and GlcNAc are represented by the rectangles and IdoA and GlcA are represented by the diamonds. (b) The 
structures of the two major repeating disaccharides of the NS and NA domains respectively. The sulfated 
residues are shown in blue. Figure produced in Chemdraw. 
1.3.4  The Three Dimensional Structure of Heparin and Heparan Sulfate 
The interactions of the heparin and HS polymer chains with proteins are determined by their sulfation 
pattern and the level of flexibility within their pyranose rings IdoA residues; as well as the rotations 
around the glycosidic linkages. Some of the information about the 3D structure has been obtained 
from NMR studies of native heparin and chemically modified heparin. The NMR studies of the 
solution structure and X-ray crystallographic studies have also been very informative in determining 
the compositions and structures of some of these heparin variations. The structure of one such 
a 
b 
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variation (dp30 where dp stands for degree of polymerisation) which was determined by 3D 1H NMR 
is shown in figure 1.15 below (Khan et al. 2010). Heparin has a right-handed helical structure and is 
made up of a 1.65 - 1.73 nm repeating tetrasaccharide sequence. It is this sequence which 
corresponds to two-fold helices with disaccharide units in its chain which are related by a rotation 
of 180°. This structure is in agreement with the structure of a heparin derived hexasaccharide 
complexed with FGF-2 (Gatti et al. 1979, Mulloy et al, 1993, Mulloy & Forster 2000). The HS 
chains are typically 50-200 disaccharide units in length meaning they are about 40-160 nm in length, 
explaining why HS chains are a dominant feature of cell membranes. The shape of heparin and HS 
chains is determined by the torsion angles of the glycosidic bonds that link the monosaccharide 
residues.  
 
Figure 1.15 – The linear model for the dp12 heparin fragment (where dp stands for: degree of 
polymerisation) the structure was determined using 3D 1H NMR. Figure made in COOT (PDB code 1HPN) 
(Khan et al. 2010) 
1.3.5  The Ring Conformations of Heparin and Heparan Sulfate 
The monosaccharide residues of heparin and HS take the 1C4 and 4C1 chair and 2S0 skew boat 
conformations. NMR and X-ray structures indicate that the rings of GlcA and GlcN residues are in 
the 4C1 chair conformation regardless of whether they are free or protein bound (Faham et al. 1996). 
The IdoA residue is more flexible, which explains how heparin and HS can bind a large range of 
proteins using their anionic groups to form bonds with the cationic binding sites on proteins. IdoA 
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exists primarily as an equilibrium of the 1C4 and 2S0 conformations, the position of this equilibrium 
depends on the position of the IdoA residue within the polysaccharide chain, as well as the 
substituents on adjacent GlcN residues (Chuang et al. 2000). The rate of interchange between the 
different conformations is fast enough to allow it to be observed in 1H and 13C NMR. The relative 
quantities of the 1C4 and 2S0 conformations are determined from 3JH-H coupling constants, and are 
roughly 40:60 for IdoA located on the reducing terminal (Chuang et al. 2000). This position of 
equilibrium is sensitive to the binding of biological molecules. The population of the 1C4 
conformation of both IdoA(2S) residues increases upon binding to histamine, this allows heparin to 
optimise its interactions with IdoA(2S) carboxylate groups. Once heparin forms a complex with 
FGF-2 the two IdoA(2S) conformations are locked in; ring C is in the 1C4 conformation and Ring E 
is in the 2S0 skew boat conformation (Faham et al. 1996). The structures of these conformations are 
shown in figure 1.16.  
  
  
Figure 1.16 – The structures of the different conformations of the GlcA, GlcN and IdoA residues of 
heparin and heparan sulfate. The IdoA monosaccharide exists as an equilibrium between the 2S0 and the 1C4 
conformations with the point of equilibrium more to the left, whereas the Glc residue exists only in the low 
energy 4C1 conformation. Figure produced in Chemdraw. 
) 
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1.3.6  The Biosynthesis of Heparin and Heparan Sulfate 
Heparin and HS both have similar synthesis pathways, their core proteins are synthesised within the 
endoplasmic reticulum before they are transported to the Golgi apparatus, at which point a 
tetrasaccharide linker is attached to areas which are rich in ser-gly repeats (Lindahl 1989). This 
linkage is then used to synthesise a repeating α1-4 linked co-polymer of D-glucuronic acid and N-
acetyl-D-glucosamine through the step-wise addition of UDP activated sugars. During the synthesis 
of this linear polymer it is modified through the action of N-deacetylase, C-5 epimerase and 2-,6- 
and 3-O-sulfotransferases. Complete modification of this polymer results in the formation of heparin 
which is N- and O-sulfo, L-iduronic acid rich. Incomplete modification of this polymer results in the 
formation of HS, which is rich in O-sulfo, N-acetyl-D-glucosamine and D-glucuronic acid (Li et al. 
1997). Although all of the enzymes that are involved with this synthesis have been identified, cloned 
and expressed it is still unclear how this process is controlled. In total 22 enzymes are associated 
with the biosynthesis process, each of which have many isoforms that are cell and tissue specific and 
as such account for the tissue specific forms of HS. As most of these enzymes have transmembrane 
regions they readily intercalate with the proximal Golgi apparatus membranes. The first controlled 
step is the formation of the tetrasaccharide linker, which starts with the addition of a xylose to the 
serine residue of the core protein by xylosyltransferase 1 or 2. This is followed by the addition of 
two galactose molecules in sequence by galactosyltransferase 1 and 2, the structure is then completed 
by the addition of GlcA by glucuronic acid transferase 1. Following this, the HS synthesis pathway 
differs from the chondroitin sulfate (CS) and dermatan sulfate (DS) synthesis pathways by the 
addition of GlcNAc over GalNAc. The elongation of the linker is controlled by a complex of EXT1 
and EXT2 (two enzymes of the EXT family) (Presto et al. 2008) the complex is responsible for the 
systematic addition of a GlcA followed by a GlcNAc moiety which gives rise to the alternating 
copolymer  found in all HS/ heparin chains. Once the chain has been fully built up the modification 
of the chain begins with the sulfation of some of the GlcNAc residues through the removal of their 
acetyl group by N-deacetylase followed by its sulfation by one of the four isoforms of N-
sulfotransferase enzymes.  NDST2 has been shown to be specific for the GAG chains which are 
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bound to serglycin which makes it essential in the process of synthesising heparin (Kreuger et al. 
2012). Once sulfation is complete further modification of the chains occurs around these regions 
which leaves these as sulfated domains/ S-domains. These sulfation domains only account for 
approximately 30% of the HS chain with the other 70% being unmodified, whilst heparin contains 
long stretches of modified disaccharides (Knox et al. 2002). After the completion of sulfation some 
of the GlcA residues are epimerized to iduronic acid with the vast majority of these being further 
sulfated at C2. The sulfation of GlcNAc and GlcNS at the C6 position is performed by one of the 
three isoforms of 6-O-sulfotransferase enzymes, whilst these enzymes are capable of performing 
both of these sulfations it has been shown that it has a preference for acting on areas with a higher 
degree of GlcNS flanked by 2 sulfated residues supporting the synthesis of longer S domains (Qin 
et al. 2015). The rarest type of modification is performed by 3-O-sulfotransferases which have the 
largest number of isoforms out of all of the HS associated enzymes. Only 3 of the 7 have a 
transmembrane region which suggests that the vast majority of them do not localise to the Golgi like 
the others (Kreuger et al. 2012). This sulfation occurs on the C3 position of the GlcNS which gives 
rise to the most highly sulfated regions of HS. Because of their similar biosynthesis pathways, all of 
the disaccharide subunits contained within the GAGs are the same; as well as some of the extended 
sequences within them such as the ATIII pentasaccharide binding sites (Lindahl et al. 1980). The 
synthesis of these binding sites needs a 3-O-sulfo group to be placed on the central glucosamine 
residue in the F position.  
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Figure 1.17 – The systematic residue modification which occurs during the biosynthesis of the heparin 
and HS polysaccharide chains. The polysaccharide chain is initially bound to its core protein at the serine 
residue via a linker tetrasaccharide. Figure produced in Chemdraw. 
1.3.7  Chemical Synthesis 
Artificial synthesis of heparin and HS is still the most common and reliable source of well-defined 
heparin and HS oligosaccharides; this is despite the considerable effort and resources required for 
the synthesis of heparin and HS, as well as the greatly diminished returns (Dulaney & Huang 2012). 
At its heart the chemical synthesis of heparin and HS involves either building up oligosaccharide 
sequences from scratch using disaccharide sequences or through the chemical modification of pre-
existing polysaccharides to include sulfate groups. Orthogonal protecting groups are placed in key 
positions in order to maintain regioselectivity and stereoselectivity during the glycosylation phase. 
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Synthetic linkers can also be added to a pre-existing sugar chain. Due to the large range and difficulty 
of reactions associated with synthesis, the yields of these reactions are often very low; however 
several studies have focused on how to overcome these issues and increase the yields (Linhardt & 
Liu 2012). Performing glycosylations with the same disaccharide building block is the most typical 
route for generating heparin/HS oligosaccharides. Using this method many compounds of differing 
lengths can be synthesised leading to the formation of compounds with regular repeating patterns in 
them. The diversity of the heparin/HS oligosaccharides can also be emulated by changing the 
functional group transformations of the basic skeleton. 
1.3.8  Interaction with proteins 
Protein binding by heparin and by HS chains is primarily electrostatic due to their large negative 
charges, it involves interactions between cationic ammonium, guanidinium and imidazolium side 
chains of proteins and the anionic sites on the heparin or HS proteoglycans. Over the years many 
heparin and HS binding proteins have been identified (Conrad 1998). The best way to identify and 
purify these proteins is through heparin affinity chromatography. This is because of the nonselective 
interactions of heparin-binding domains with anionic heparin (Salmivrta et al. 1996). This 
information has led to the thought that all heparin-protein interactions are nonspecific, however there 
is now a key train of thought that sequences in the NS domains and NA domains of the HS chains 
are designed for selective interactions with specific proteins, it is these interactions which result in 
the regulation of heparin binding protein activities. Selectivity in the binding can be achieved through 
the use of GlcNS(3,6S) which is present in the antithrombin-binding sequence of heparin and 
essential for its anticoagulant activity (Lindahl et al. 1998). The pattern of N-substitution present 
may also play a part in a unique binding epitope as well as the combination of N- and O-substituents 
or even the length and positions of the NS, NA and NS/NA domains may also have an effect. Other 
known protein binding sequences are made up of common disaccharides; typically there are 3-9 
disaccharide units are involved with protein binding although longer sequences that wrap around the 
surface of protein oligomers can sometimes be involved. Heparin binding domains have been 
identified in a large number of proteins; typically they contain large numbers of lysine and arginine 
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and in some cases histidine (Rabenstein 2002). The X-ray structure of the hexasaccharide complex 
with FGF-2 shows that the functional groups of the side chains on some of the amino acids can also 
interact with binding sites on heparin. Several heparin binding domains have been observed in large 
quantities on multiple proteins. X-ray studies have detailed that the side chains of certain other amino 
acids (e.g. the amide side chains of arginine and glutamine) also interact with sites on 
heparin.  Several consensus sequences have been proposed as the heparin binding sites on the 
proteins. These sequences are made up of basic residues and include the sequences: XBBBXXBX, 
XBBXBX and XBBBXXBBBXXBBX; where B and X are basic and hydropathic residues 
respectively. These sequences have been proposed to adopt secondary structures where the basic 
residues are aligned along one exposed face and the X amino acids point into the protein core. Due 
to their high negative charges heparin and HS are polyelectrolytes with a fraction of their negative 
charge neutralised by bound counter cations. This supports the idea that the binding reaction is an 
ion exchange process, with the cationic sites of the bound peptides serving as counter ions (Sobel et 
al. 1992). 
1.3.8.1  Interaction of a Heparin Disaccharide with Heparinase II 
Native low molecular weight heparin disaccharide molecules were introduced to a solution of native 
heparinise II (HepII) in order to visualise the heparin binding site. The structure of heparin bound 
HepII was determined to a resolution of 2.30 A. The structure of the HeppII crystalised with the 
heparin disaccharide showed that the heparin binding site is a deep, elongated 30-35 A canyon that 
is formed at the top of the N-terminal domain and also includes several loops from the central 
domain. A central ridge divides the canyon into two distinct halves, one narrow and shallow and one 
narrow and deep. The nonreducing end of the disaccharide was found to bind directly to the deeper 
half of the binding site. The canyon is maintained by a series of hydrogen bonds produced by a series 
of mainchain and sidechain atoms, including the Tyr-436, Asn-405, Arg-261, Glu-205, and Arg-148 
residues. The final three residues also form salt bridges with the uronic acid component of heparin. 
The uronic acid is held within the binding site through interactions with the His-406, Arg-261, Glu-
205, and Arg-148 residues. Shaya et al. 2006 
Chapter 1 
Page 40 of 141 
 
1.3.8.2  Interaction of heparin with a mutant heparin lyase 
Heparinase I (Hep-I) is a heparin lyase that specifically depolymerises heparin molecules by cleaving 
the glycosidic linkage of the iduronic acid residues. The structure of Hep-I comprises of a β-jelly-
roll domain containing a long, deep substrate binding canyon formed by the inner sheet of the 
domain. The binding site of Hep-I consists of the Glu73, Tyr75, Lys185 and Asp253 residues and is 
partially covered by a lid formed by two loops comprising of the Gly74-Glu79, Thr250-Asn257 and 
the Lys184-Val187 residues. The structural integrity of this domain is aided by a Ca2+ ion, bound to 
the hinge region of Hep-I. The canyon has been found to have a strong positive charge, favourable 
to forming ionic interactions with a strong negatively charged molecule such as heparin. During 
heparin binding, the Thumb domain of Hep-I has been noted to move towards the substrate. Han et 
al. 2009. 
1.3.9  Clinical Applications of Heparin 
The classical use of heparin has been as the major anticoagulant drug of the past 60 years, its main 
function is to inhibit the formation of clot and thrombi. This is especially important during and after 
invasive surgery such as open heart surgery or after the body has experienced trauma. Heparin is one 
of the most prolific drugs used today, second only to insulin. The reason that it is so widely used is 
because it interacts with many of the proteins that are associated with the blood clotting cascade such 
as thrombin and antithrombin. The usefulness of heparin as a clinical drug primarily stems from its 
ability to bind to antithrombin and accelerate its activity, which results in fast and increased 
inhibition of the coagulation factors Xa and IIa. In a biological sense the mode of action that heparin 
is involved in is more akin to a defence mechanism against exogenous pathogens and damage 
limitation during tissue damage; heparin accomplishes this by altering cytokine levels in response to 
trauma or infection. Heparin limits the release of proinflammatory cytokines such as IL-1, IL-8 and 
TNFα whilst promoting the release of anti-inflammatory cytokines such as IL-10 (Lima et al. 2017).  
Exogenous heparin is clinically used as an anticoagulant and is the initial choice for an anticoagulant 
of use in the treatment and prevention of thromboembolic diseases. HS with its universal distribution 
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in animal tissues also has a wide range of functions including cell adhesion, regulation of cell growth 
and proliferation, development processes, an effect on blood coagulation, cell surface binding of 
lipoprotein lipase and other proteins, angiogenesis, viral invasion, tumour metastasis, protection 
from protein degradation, regulated protein transport through membranes and mediates the 
internalisation of proteins. HS proteoglycans on the cell surface is in a dynamic state of being 
constantly trafficked rapidly to the cell surface and turning over quickly, with its structure constantly 
changing in response to extracellular signals like growth factors. The method of action displayed by 
heparin and HS revolves around non-covalent interactions with other proteins to effect changes in 
their conformation to facilitate protein to protein interactions allowing for protein sequestration and 
to function as co-receptors for growth factors (Mulloy & Forster 2000, Rabenstein 2002). 
1.3.10  Inhibition of Blood Coagulation 
Coagulation of the blood relies on a host of precursor-serine protease reactions, which activate to 
produce thrombin. Thrombin then produces fibrin which is the primary crosslink in a blood clot. 
Coagulation is usually regulated by antithrombin which is a serine protease inhibitor, antithrombin 
is relatively inactive in its natural state and requires an interaction with HS in order for it to act as an 
inhibitor. Heparin acts as an inhibitor as it complexes with antithrombin (hence is an activator) so it 
accelerates the rate at which serine proteases are inactivated (Rabenstein 2002). Because of this 
activity it is used as a clinical anticoagulant; however because it naturally sequesters in mast cell 
granules it is argued that heparin is not a natural anticoagulant. The unique antithrombin binding 
pentasaccharide that is associated with heparin mediates the anticoagulant activity of heparin. The 
pentasaccharide is required for the inactivation of factor Xa by antithrombin; however a much longer 
sequence which includes the pentasaccharide is required for the inactivation of thrombin. Only about 
50 % of all heparin is anticoagulant active (binds to antithrombin) the main way that this fraction 
was identified was through observing the interactions of oligosaccharides produced from the recent 
depolymerisation of heparin with 1H NMR. In order for thrombin to be deactivated the larger 
sequence needs to first bind the thrombin using a separate binding sequence and then bind to 
antithrombin and bring the two together so they can form a tight complex (Dowd et al. 1999). 
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1.3.11  Heparin Induced Thrombocytopenia  
Heparin induced thrombocytopenia (HIT) is a severe side effect of heparin treatment for blood clots; 
it is caused by heparin dependent IgG antibodies which are generated against the platelet factor 4 
(PF4)/ heparin complex. This complex is formed when PF4, a member of the C-X-C family of 
chemokines binds to heparin molecules. PF4 does this through its lysine rich moieties which follow 
the typical amino acid binding sites for heparin found on proteins (Ziporen et al. 1998). The heparin 
molecules “bundle” the PF4 molecules which results in a conformational change of the PF4; these 
changes then become the binding sites for the HIT-IgG. There are several of these binding sites on 
PF4, recent studies have discovered that they are located on the apposition points where PF4 
tetramers are brought into proximity through charge neutralisation by heparin there is a minimum 
charge density and chain length required for heparin interaction with PF4. The complex of antibodies 
and H/PF4 activate the FcyRIIa receptors on platelets. The need for this conformational change was 
proved by Horsewood et al. when they performed an experiment on unbound, linear PF4 which 
would not bind to HIT-IgG but it would bind when it was in the presence of heparin which proved 
that these conformational changes were brought about by the binding of one heparin molecule to 
four to eight PF4 molecules (Carter et al. 2005). 
PF4 is a small 70 residue long protein with four carboxyl-terminal positively charged lysine rich 
regions which are used to bind heparin. Additionally PF4 contains four cysteines that are used to 
form internalised disulfide bonds (Poncz et al. 1987). The Pro37 residue located near the surface of 
the tetramer on the side opposite the heparin binding sites, was found to be a key IgG binding residue 
when it was substituted for an N residue which was not expected to cause a structural change in the 
binding site. Despite this, once this substitution had occurred IgG was no longer able to bind to the 
H/PF4 complex which proved that P37 was important to IgG binding. Because P37 is far (relatively) 
away from the heparin binding rings it is thought that once the heparin binds to the complex the P37 
is exposed; as well as the four amino acids which are adjacent to the P37 and the homologous 
residues in neutrophil activating peptide-2 (NAP-2) all of which are buried in a hydrophobic pocket 
created by beta sheet strands (Ziporen et al. 1998).  
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The stability of the heparin/PF4 complex depends on the relative concentrations of heparin and PF4 
and can be characterised by their size and the nature of the electrostatic surface charge interactions. 
It has been observed that when not in the presence of heparin the PF4 particles are dispersed due to 
their strongly positive electrostatic charges repulsing each other. However these positive charges are 
neutralised by increasing the concentration of heparin leading to macromolecular aggregation. Once 
heparin is in molar excess the repulsive forces start to build up again which leads to the dispersion 
of the molecules once again (Suvarna et al, 2007). Other studies have found that these macro 
aggregates can differ in terms of size, charge and composition depending on the type of heparin that 
was used as well as the physiological conditions used. It was found that the larger complexes formed 
when a higher concentration of PF4 was used (the biggest formed with a PF4-heparin molar ratio of 
13:1) (Bertini et al, 2017). The majority of pharmaceutical grade heparin is porcine in origin due to 
the fear of prion contamination in bovine and ovine sources, however in 2007 and 2008 there were 
several reported cases of porcine heparin from China with over O-sulfated chondroitin sulfate which 
resulted in fatalities. As a consequence the US is now considering supplementing the porcine heparin 
with bovine heparin which is still commonly used in some South American countries (Guerrini et 
al. 2008). It has been shown however that ovine heparin requires a lower [PF4] than both porcine 
and bovine heparin; this effect may be due to the higher average molecular weight and sulfation 
levels found in ovine heparin (Bertini et al. 2017).  
1.3.12  Low Molecular Weight Heparins  
The low-molecular-weight heparins (LMWH) are one of the most important forms of heparin in 
regards to clinical use. This class of heparin is made up of a mixture of heparin derived fragments 
which range from tetra to hexadecasaccharides; they are obtained via a wide array of chemical and 
enzymatic depolymerisation reactions (Viskov et al. 2009). The reason that LMWHs are thought to 
be superior to unfractionated heparin (UFH) is because they have a higher bioavailability and a 
higher anti-factor Xa/ anti-factor IIa activity by comparison to UFHs as well as a decreased 
haemorrhagic risk during surgery (Hoppensteadt et al. 2005). However LMWHs cannot be 
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monitored and their action cannot be reversed during procedures due to neutralisation with protamine 
sulfates being ineffective, so this carries an increased risk of HIT (Xu et al. 2012a).  
LMWHs also have some potential as a treatment for cancer related haemostatic disorders through 
the modulation and control of FGF signalling pathways between cancerous cells (Xu et al. 2012b). 
LMWHs are once again the more desirable treatment due to their much more predictable 
anticoagulant response which is important in order to control any potential bleeding associated with 
the cancer and their extended half-life within the body, as well as having a reduced chance of causing 
HIT (Rickles & Falanga 2001). The prevention and treatment of these cancer-related haemostatic 
conditions as well as controlling the expression of tumour cell-associated clotting factors has a clear 
and direct impact on not only the easing of the associated symptoms but to the survival of the cancer 
patients. Whilst LMWH and HS have the often unwanted side effect of anticoagulation activity when 
being used to treat cancer, they do have the ability to alter signalling defects as well as the activity 
of sulf enzymes. Due to their role in the partial inhibition of the inflammation response it has been 
proposed that heparin could be used as a potential treatment of cystic fibrosis through the inhibition 
of elastase (Lima et al. 2017).  
Due to the presence of LMWHs on all cell surfaces they are expected to act as broad-spectrum non-
specific virus-binding receptors, this interaction is backed up by the fact that viral envelopes present 
patches of electropositive amino acids. It has been long known that viruses have the ability to bind 
to surface heparin and HS (in the form of herpes simplex and dengue virus). Because of its virus 
binding capabilities heparin has been suggested as a potential inhibitor for viral attachment; the 
theory of which has been proved through experiments carried out with dengue virus, however what 
this did not explain was how the process could be used to allow heparin to be used as efficient 
inhibitors (Lin et al. 2002). Heparin has also been shown to act against infection from influenza 
H5N1as well as acting on the fusion envelope protein of the Zika virus and preventing the 
programmed cell death that is associated with the virus by preventing its adhesion (Ghezzi et al. 
2017). 
Chapter 1 
Page 45 of 141 
 
1.4 Aims and Objectives 
The main aim of this work was to determine the mechanism via which, the Fc region of human IgG 
binds to specific analogues of the heparin polymer. The secondary aim of this work was to determine 
what effect this interaction had on the structure of the two molecules, in order to observe the 
implications to the functionality of the two molecules. To this end, the work initially focused on a 
wide range of ligand binding studies of human IgG-Fc, with a specific focus on the well conditions 
that produced crystals which diffracted to a high resolution. This area was focused on as it would 
provide a starting point for the crystallisation trials, required to obtain a structure of this interaction. 
Once this interaction had been observed, work would then have moved on to focusing on the binding 
mechanisms and affinities of other heparin polymers with the IgG-Fc, as well as comparing and 
contrasting their binding mechanisms to each other. 
In order to do this, two samples of human IgG were prepared. The first of these samples was a native 
Human IgG-Fc fragment derived from Human Sera and procured from Bethyl Laboratories (Cat: 
P80-104), from here on referred to as native IgG. The second protein sample was a recombinant 
Human IgG-Fc fragment procured from Sino Biological (Cat: 10702-HNAH), from here on referred 
to as recombinant IgG-Fc fragment. The amino acid sequence of this sample included residues from 
Glu99-Lys330 and a single Cys/Ser mutation was introduced at Cys103. In addition to this, the 
expression hosts for this sample was HEK293 cells. 
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Chapter 2 – Mass Spectrometry Analysis and Sequence Determination 
2.1  Introduction 
2.1.1  An Introduction to Proteomics 
Proteomics is the large scale study of the genetic information contained within the sets of proteins 
produced by an organism, otherwise known as a proteome. Specifically proteomics aims to explain 
the structural and functional information stored within the proteomes (Fraser et al., 1997). Proteomes 
are not static and can be different between cells and can change over time. Proteomics can be used 
to study a wide variety of protein characteristics such as: protein expression, the life cycle of proteins 
and protein modification. Because of this, proteomics is often thought of as a genome-wide assay 
which can differentiate and study cellular states (Fraser et al., 1997). The production of genomic 
DNA marker databases has expedited the evolution of proteomics as a technique to the point where 
studying hundreds of thousands of proteins is a realistic and rapid process (Fraser et al., 1997).  
In proteome analysis, it is expected that any data which is obtained by direct proteome analysis 
complements the data that is obtained by more readily available methods of proteome analysis such 
as high throughput gene sequencing (Aebersold and Goodlett, 2000). Despite recent advances in 
proteome analysis, it is still largely impossible to determine the certain properties of proteins using 
proteomics alone; such as their location. Mass spectrometry (MS) techniques largely focus on 
protein-protein interactions and post-translation modifications (Aebersold and Goodlett, 2000). 
The classical approach to proteomic research has been through the purification and homogeneity of 
the proteome via sequential fractionation and assay cycles. However, these techniques have been 
superseded by more powerful modern techniques like mass spectrometry (Fraser et al., 1997).  
2.1.2  An Introduction to Mass Spectrometry  
MS is an analytical chemical technique where the analytes are ionised and the ratio of their mass to 
charge is measured. MS was discovered in the early 1900s however its use was only limited to 
chemical sciences. The invention of Electrospray ionisation and Matrix Assisted Laser Desorption/ 
Ionisation (MALDI) in the 1980s allowed biological molecules to be analysed by MS (Singhal et 
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al., 2015). Recently, large protein masses of over 100,000 Da have been determined, this means that 
because of the ease with which proteins can be ionised, MS is considered to be an excellent 
complementary technique to the more classical techniques of protein analysis; such as nuclear 
magnetic resonance (NMR), circular dichroism and x-ray diffraction (Vertes, 2008). Since its 
introduction, MS has had much success in studies of the primary, secondary, tertiary and quaternary 
structures of proteins, as well as in studies of the structures of folded polypeptides (Chait et al., 
1992).  
Mass spectrometers are made up of an ion source, a mass analyser which measures the mass to charge 
ratio (m/z) of the analytes and a detector which registers the ions which strike it. A computer then 
records the number of ion strikes at each m/z value and provides a readout. The two most commonly 
used proteomic mass spectrometric techniques are Electrospray Ionisation (ESI) and MALDI 
(Spengler et al., 1992). There are four types of mass analysers that are commonly used in proteomics: 
Ion trap, time-of-flight, quadrupole and Fourier transform ion cyclotron (FT-MS) analysers (Bruno 
and Ruedi, 2006). Despite all having the same purpose, the ways in which these analysers function 
is very different and they all have their own strengths. Ion trap analysers are robust and inexpensive 
(relative to the other analysers which are available), however they are far less accurate in determining 
the mass of the peptide analytes. They work by trapping the ions for a length of time before being 
subjected to MS/MS analysis. The FT-MS analyser traps the ions in a high vacuum using a strong 
magnetic field; whilst it is much more accurate and sensitive, it is extremely expensive and has very 
poor peptide fragmentation efficiency and as such is not often used for proteomic evaluation. Time-
of-flight (TOF) analysers are used when measuring intact peptides (Aebersold and Goodlett, 2000).  
2.1.3  MALDI – TOF MS 
MALDI is an MS technique which was developed by Karas and Hillenkamp in the 1980s. It produces 
singly charged ions either through the addition or loss of a single proton. Due to the fact that there 
is minimal sample fragmentation during MALDI analysis it is described as a soft ionisation 
technique. The sample used in MALDI is prepared by mixing the analyte with a solution of an energy 
absorbent, organic compound called the matrix. The matrix crystallises when dry, trapping the 
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analyte within the crystal complex as a co-crystal (Patterson, 1995). The matrix is then exposed to a 
laser beam, during this process the matrix absorbs light at the ultraviolet wavelength of 337nm and 
converts the light to heat energy; this causes a small amount of the matrix (100nm depth) to heat up 
and vaporise along with the sample (Patterson and Aebersold, 1995; Singhal et al., 2015).  
As with the other MS techniques the protonated ions are accelerated under a known fixed potential, 
this then causes the ions to separate based on their m/z and detected by the detector (Patterson and 
Aebersold 1992). TOF detectors are used for biological molecules such as proteins, during the 
MALDI-TOF analysis the m/z of an ion is determined by the length of time it takes for the ion to 
travel to the detector (Webster and Oxley, 2009). Some types of TOF analysers contain a mirror at 
the end of the flight tube which bounces the ions back towards the detector, this effectively doubles 
the length of the flight tube which in turn allows for smaller machines as well as correcting small 
energy differences within the sample (Wilm & Mann, 1996). 
Identification of molecules by MALDI TOF is performed by comparing the peptide mass fingerprint 
(PMF), (the spectrum produced based on the TOF information of the molecule) of the molecule with 
PMFs contained within a database such as the mascot database. The main issue with peptide analysis 
using MALDI TOF is that it has an inherently reduced resolving power. This is caused by the spread 
of a small amount of kinetic energy during the ionisation process. This reduction in resolving power 
means that the natural isotope distribution of the peptides cannot be observed. Historically, two 
instruments have been developed in order to combat these effects; the first, a reflectron is a device 
which applies a decelerating voltage to the opposite end of the flight tube to the ion source (Wiley 
& McLaren, 1955). This decelerating voltage is higher than the accelerating voltage and as such 
“reflects” the ions back towards a secondary detector which is next to the ion source. Reflectrons 
work on the basis that higher energy isotopes will penetrate further into this voltage than lower 
energy isotopes before being reflected. This means that the higher energy isotopes will strike the 
detector at the same time as their lower energy counterparts as their flight path is longer (Wiley & 
McLaren, 1955). The second device is called a time-lag focuser. This device works by waiting a few 
second after the ions are produced to apply the accelerating voltage, this results in the energy of the 
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higher energy ions being reduced to a level closer to the lower energy ions resulting in a higher 
resolution (Vestal et al., 1995). 
2.1.4  An Introduction to ESI Mass Spectrometry 
ESI-MS is a MS technique, developed in the late 1980s to the early 1990s which is capable of 
analysing molecules with a range of molecular weights and polarities within a biological sample. 
ESI uses electrical energy to ionise molecules and transfer them into the gas phase (Dewald, 2009). 
This is especially effective when the analyte is in solution. This change of phase contains three steps, 
the first of which is the dispersal of a fine spray of charged droplets. The electrical field strength 
becomes high enough where it causes the solvent drops to evaporate which causes the ions at the 
surface of the drop to be ejected in the gaseous phase. These ions are then sampled by a skimmer 
cone before being accelerated into the mass analyser (Charles, McLukey and Glish, 1994).  
During the nebulisation stage the sample solution is fed into a capillary tube into a high electric field 
at the tip of the tube. This electric field pulls positive charge towards the front of the liquid, when 
the electrostatic force overcomes the surface tension of the small charged droplets. The droplets then 
travel through the inert gas to the counter electrode. The capillary tube is more positive than the 
electrode. Electrospray is defined as the dispersion of electrically charged droplets, in order to do 
this two steps are required, they are the droplet formation and charging. The forming of these droplets 
does not present an issue if the flow rate, surface tension and electrolyte concentration are low 
enough; if one of these variables increases it makes it more difficult for the electric field to produce 
the required aerosol charge (Bruins, 1998). The strength of the electric field at the tip of the capillary 
can be increased in order to overcome any of the adverse effects that are produced by changes in the 
variables. However if the electrical field is too high, an electrical discharge will occur alongside the 
electrospray ejection, the consequence of this is disruption of the drop formation. In the majority of 
ESI situations positive charge on the droplets is produced by the removal of the negative charge by 
discharging the negative ions against the metal wall of the capillary (King et al., 2000). In some 
conditions it is possible to directly remove electrons from molecules that have a low ionisation 
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energy. Because the electrons are consumed in order to neutralise the positive ions in the positively 
charged droplets, an ESI source is an example of an electrolysis cell (Bruins, 1998). 
The ions are evaporated once the strength of the electric field overcomes the surface tension of the 
drop. However if the ions have more than one solvation shell it may separate from the droplet as a 
nanodrop which loses the solvent molecules during its flight time. Both of these processes leads to 
naked sample ions which are taken into the mass spectrometer. If a sample ion has not been 
desolvated before it enters the vacuum system it will be desolvated when it passes through the curtain 
gas (Ho et al., 2003). 
ESI mass spectrometers are usually paired with a quadrupole mass analyser which is an assembly of 
four equidistant metal rods which run parallel to each other. The rods are arranged so that each rod 
is placed in a different corner of an imaginary diamond. The pairs of opposite rods are electrically 
connected, with a DC voltage superimposed with an equal but opposite AC voltage. The electrical 
field that results from this arrangement causes the analytes to travel along the rods (in the Z plane) 
whilst oscillating in the X-Y plane. The amplitude of this oscillation is directly related to the m/z of 
the analytes and is controlled by the DC and AC voltages in order to prevent the analytes from hitting 
the quadrupole rods, allowing them to travel their full lengths into the detector. This means that 
undesirable ions can be neutralised and removed before they reach the detector (Jonscher & Yates, 
1997).  
During ESI-MS the signal is directly proportional to the analyte concentration and is mostly 
independent of the flow rate that is used for the introduction of the sample, hence ESI acts as a 
concentration sensitive detector. Because of the relative softness of their ionisation, both ESI and 
MALDI have been used to generate intact ionic proteins, with non-covalent interactions. Other ESI 
based studies have focused on the use of hydrogen-deuterium exchange in order to examine some 
higher order structural features (Akashi, Naito & Takio, 1999). An example of a structural feature 
which can be examined using this technique is solvent accessibility; this is based on the observation 
that hydrogen atoms which are exposed to solvent are exchanged with deuterium atoms at an 
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increased rate compared to hydrogen atoms which are shielded from solvent. This technique can also 
be used to detect hydrogen bonding within a protein, this is based on the observation that hydrogen 
atoms bound up in hydrogen bonds exchange at a slower rate than hydrogen atoms that are not 
involved in hydrogen bonds (Akashi, Naito & Takio, 1999). Using this concept the denaturation of 
an α-helix has been observed by Anderegg et al. Other experiments have proved without the use of 
H-D exchange that ESI-MS can be used to monitor the denaturation of proteins in solution (Katta & 
Chait, 1991). These experiments use the observation that the mass spectra produced by ESI-MS of 
denatured proteins show a higher charge state than those of an identical protein that has not been 
denatured. Other applications of ESI-MS in the study of higher order protein structure include the 
identification of residues which are juxtaposed residues through cross-linking with side-chain 
specific linkers (Konermann et al., 1997; Loo et al., 1991; Mirza, Cohen & Chait, 1993).  
When speed and sensitivity of ESI is greatly increased when it is coupled with high performance 
separation techniques, such as High Performance Liquid Chromatography (HPLC) or Fast Protein 
Liquid Chromatography (FPLC). This is because their implementation reduces the amount of peptide 
required for complete sequence characterisation to a femtomolar level (Aebersold and Goodlett, 
2000).  
2.1.5  The Principles of Peptide Mass Mapping 
Peptide mass mapping is based on the observation that proteins which undergo proteolysis with a 
specific protease, produce much shorter polypeptide sequences. The masses of these sequences 
create a unique mass finger print for that protein and that protein only (Patterson & Aebersold 1998). 
This means that if a protein database is searched using the selected mass fingerprint then the protein 
which the fingerprint originated from should be correctly identified. The basic techniques which can 
be used to automate peptide mass mapping are as follows: The sample protein is lysed using 
sequence specific cleavage enzymes. These enzymes target specific residues which means that any 
peptides they produce will have known amino and carboxylate terminals. The peptides are then 
analysed using mass spectrometry to determine their masses (Webster et al., 2009). The database 
search is then performed by digesting the proteins it contains in silico using the same enzyme as was 
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used in the experiment. This produces a list of possible theoretical masses which are then compared 
to the set of experimental masses. During this comparison, an algorithm assigns a score to each of 
the theoretical masses depending on how well they match the set of experimental masses, where a 
higher score indicates a better match (Henzel et al., 1998).  
Peptide mass mapping does however have some limitations, for example; as protein determination 
requires several peptide masses, which are derived from the same protein to correlate with a set of 
experimental masses, it is not suitable for use when the target protein is in a mixture of several 
proteolysed peptides (Patterson and Aerbersold 1998). This is because it is often difficult to 
determine which peptides in the mixture correlate to a specific protein. Another limitation of the 
technique is that when a pure protein sample is digested and analysed not all of the predicted peptide 
peaks may be observed and some of the observed peptide masses may not be present in the database. 
Predicted peaks are typically not observed due to a number of issues that can arise before analysis; 
these include: poor sample solubility, selective ionisation, the peptides being very short and the 
introduction of contaminants to the sample. Unassigned peptide masses indicate a much greater 
problem as they can easily lead to misidentification of the sample. Unassigned masses are observed 
when; the mass of the target peptide is changed due to post-translational modifications, it is changed 
through artificial modifications which are introduced during the preparation of the sample. 
Unassigned peaks can also be observed when the sample has not been completely proteolysed or 
contaminant proteases have been introduced during preparation. The final reason for unassigned 
peaks is that there are multiple proteins in the sample, which is usually caused by contamination 
during sample preparation (Jensen et al. 1996).  
2.2  Aims 
Due to the fact that the Fc fragments that were to be used for the structural studies were purified 
from human serum, there was a chance that any of the four common subtypes could have been 
present within any crystals that were produced.  
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2.2.1  Methods 
In order to determine which subtype was present within the protein crystals the IgG Fc sample was 
subjected to two different mass spectrometry (mass spec) techniques: Matrix Assisted Laser 
Desorption/Ionisation Time of Flight (MALDI-TOF) and Electrospray Ionisation (ESI) mass 
spectrometry.  
2.2.2  Materials 
A 100 mM solution of NH4HCO3 was produced by dissolving NH4HCO3 in filtered, deionised water, 
a 50mM stock of NH4HCO3 was then prepared using this solution. RapiGest (Waters) was suspended 
in 50 mM NH4HCO3 to produce a solution of 10mg/ml. A 1mg/ml trypsin solution was then 
produced by trypsin in 1mM HCl. A 100mM solution of DL-dithiothreitol (DTT) was prepared by 
dissolving DTT in deionised H2O. iodoacetamide (IAA) was dissolved in deionised H2O to prepare 
a 100mM solution. Finally a 30%v/v solution of trifluroacetic acid was prepared. 
2.2.3  Production of Peptide Fragments for Proteomics 
A 10 pmol/µl sample of the IgG-Fc from human serum was taken from a previously prepared 8mg/ml 
stock solution (please see section 3.2.1.1 for details), 13µl of the Rapigest solution was added to this 
sample followed by 7µl of the DTT solution. Once both of these solutions were added to the sample, 
the sample was heated to 80˚C for 15 minutes; the sample was then allowed to cool to room 
temperature before it was vortexed gently for 30 seconds. Next 13µl of the IAA solution was added 
before the sample was incubated in the dark for 60 minutes. After this, a further 18µl of the DTT 
solution was added to the sample, 25µl of the prepared NH4HCO3 solution was added to the sample 
to give the sample a final volume of 125µl.  
The sample was then divided into two equal aliquots of 62.5µl each. The trypsin and GluC solutions 
were both diluted to 1:10 solutions of 10µl each. 1.2µl of the trypsin solution was added to one of 
the samples and 1.2µl of the GluC solution was added to the other. Both of the samples were then 
incubated at 30˚C for 8 hours before a further 1.2µl of trypsin digest and the GluC digest was added 
to their respective samples and the samples were incubated at 30˚C for a further 16 hours. In order 
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to stop the reaction 1µl of the TFA solution was added to each sample, the samples were then 
incubated at 37˚C for 45 minutes before being centrifuged at 13,000 rpm for 10 minutes. 
2.2.4  Data Analysis 
Data analysis was performed using the MASCOT server. The mass peaks produced by MALDI and 
ESI were compared with the in silico library of digested peptides and assigned a score based on how 
well they matched the library peptides. For the MALDI datasets, this library search was performed 
with a lower bound mass cut-off of 100 ppm and a maximum of 1 missed cleavage for both the GluC 
and trypsin digests. This narrowed down the library to peptides that fell under these conditions, these 
peptides were then reduced to only those that could have originated from human IgG-Fc. It is these 
peptides that the MALDI digests were compared to.  
For the ESI results; the mass cut-off was increased to 200 ppm and the number of potential missed 
cleavages was increased to two. This was because the initial results only contained 7 hits and by 
increasing these parameters an additional 3 hits came back whilst still allowing a high degree of 
confidence that they were indeed peptides that could have originated from IgG-Fc. 
2.3  Results 
2.3.1  MALDI Results 
Two proteolytic digests were carried out on the IgG-Fc from sera, one with the enzyme trypsin and 
the other with GluC. This was performed alongside the electron density analysis as a complementary 
technique in order to determine the sequences of the IgG-Fc isoforms that were present in the 
solution to aid in the sequence determination. The spectrum of the MALDI sample which was 
digested with trypsin showed ten clear peaks which corresponded to nine known sequences within 
the IgG-Fc region which are shown in figure 2.1. One of the sequences: K.DTLMISR.T was 
identified twice by the search. The peak at 835.4093 identified the sequence without any form of 
methionine oxidation and the peak at 851.4106 indicated the same sequence with oxidation of the 
methionine residue, thus giving it an Mr that was roughly 16 Da greater. There were also several 
smaller peaks which could have been associated with some of the other sequences that are typically 
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associated with the Fc fragment of IgG which were identified using the peptide mass program which 
is a part of the UniProt web server (Wilkins et al., 1997; Gasteiger et al., 2005). The spectra did 
however contain a high degree of noise which made the identification of some of the smaller peaks 
difficult and contributed to the low degree of identification.  
The MALDI was able to identify 10 sequences with the number of missed cleavages set to 2 and the 
mass cut-off set to 100 ppm, this cut-off was chosen as having a smaller cut-off would have resulted 
in the identification of sequences that were too short to be useful and a higher cut-off would have 
reduced the accuracy of the results. All of these sequences identified the subtype that was present 
was IgG1, however the sequence coverage was only 35% and so was not enough to tell what the full 
sequence was or even which of the subtypes was actually present as some of these sequences were 
also present in the other subtypes as well. These sequences alongside the sequence coverage are 
shown in figure 2.2.  
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Figure 2.1 – Mass Spectrum of the Trypsin Digest of the Human IgG-Fc purified from Sera 
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(A) 
1 ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV 
51 HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP 
101 KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS 
151 HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK 
201 EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC 
251 LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW 
301 QQGNVFSCSV MHEALHNHYT QKSLSLSPGK   
(B)      
Start – End Observed Mr(expt) Mr(calc) ppm  M Peptide 
132 – 138 835.4093 834.4020 834.4269 -29.9 0 K.DTLMISR.T 
132 – 138 851.4106 850.4033 850.4218 -21.8 0 K.DTLMISR.T + Oxidation (M) 
139 – 157 2138.9311 2137.9238 2138.0202 -45.1 0 R.TPEVTCVVVDVSHEDPEVK.F 
158 – 171 1677.7318 1676.7245 1676.7947 -41.9 0 K.FNWYVDGVEVHNAK.T 
185 – 203 2228.1004 2227.0931 2227.2001 -48.0 1 R.VVSVLTVLHQDWLNGKEYK.C 
206 – 217 1266.6960 1265.6887 1265.7343 -36.0 1 K.VSNKALPAPIEK.T 
210 – 217 838.4753 837.4680 837.4960 -33.4 0 K.ALPAPIEK.T 
224 – 243 2311.1040 2310.0967 2310.1968 -43.3 2 K.GQPREPQVYTLPPSRDELTK.N 
244 – 253 1161.5739 1160.5666 1160.6223 -48.0 0 K.NQVSLTCLVK.G 
276 – 292 1873.8429 1872.8356 1872.9146 -42.1 0 K.TTPPVLDSDGSFFLYSK.L 
Figure 2.2. (A) The sequence coverage of the peptide sequences that were produced by MALDI mass spectrometry for the Trypsin digest of the native Fc fragment 
from sera. The start of the CH2 domain is shown in green and the matched peptides are shown in bold red. (B) The data for the peptide sequences of the native IgG Fc from 
sera that were identified by the MALDI for the trypsin digest.
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The MALDI spectrum for the GluC digest also had some large clear peaks as shown in figure 2.3 
below, for example the peak at 1752.8345. There were also many more of the smaller peaks as well 
as a much higher level of noise than the trypsin digest and as such it was more difficult to identify 
any additional peaks usually associated with a GluC digest of IgG-Fc. The analysis of the spectra by 
the Mascot server was not able to detect any sequences that were associated with the Fc fragment 
however it was able to identify 17 sequences from the Allophycocyanin alpha subunit of 
Synechococcus sp. (ATCC27264), these sequences are shown in table 2.1. There were also 16 
sequences that were associated with the Methylenetetrahydrofolate-tRNA-(uracil-5-)-
methyltransferase of Bacillus subtilis (strain 168). These sequences are shown in table 2.2.
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Figure 2.3. MALDI Mass Spectrum of the GluC Digest of the Human IgG-Fc purified from Sera 
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Table 2.1. The mass spectrometry data for the sequences of the Allophycocyanin alpha subunit of Synechococcus sp. Strain ATCC27264 that were identified by 
the MALDI for the GluC digest. 
Observed   Mr(expt)   Mr(calc)    ppm Start   End Miss  Peptide 
859.4105   858.4032  858.4923   -103.79 49  -  56  0    E.RIIKSAGD.A 
971.4598   970.4526   970.5447   -94.97 106  -  114  1    E.EIGLVGVRE.M 
983.4484   982.4411   982.4212   20.3 77  -  84  0    E.MTATCLRD.M + Oxidation (M) 
1329.525   1328.5182  1328.5411   -17.19 133  -  145  1   E.MKAVATGMMSGDD.A + Oxidation (M) 
1345.5399 1344.5326  1344.5360   -2.50 133  -  145  1   E.MKAVATGMMSGDD.A + 2 Oxidation (M) 
1493.8125 1492.8052  1492.7443   40.8 1  -  14  1   E-.MSIVTKSIVNADAE.A + Oxidation (M) 
1584.6636 1583.6563  1583.6629   -4.18 133  -  148  2   E.MKAVATGMMSGDDAAE.A 
1600.7476 1599.7403  1599.6579   51.5 133  -  148  2   E.MKAVATGMMSGDDAAE.A + Oxidation (M) 
1808.8470 1807.8397  1807.7611   43.5 145  -  161  3   D.DAAEAGAYFDYVIGAME.- + Oxidation (M) 
1814.7542 1813.7469  1814.0162   -148.46 49  -  64  1   E.RIIKSAGDALFQKRPD.V 
1933.0139 1932.0066  1932.0905   -43.39  25  -  41  1   D.RIKAFVTSGESRLRIAE.T 
2039.0393 2038.0320  2037.9646   33.1  125  -  144  1   D.AVAQAVREMKAVATGMMSGD.D + Oxidation (M) 
2079.0062 2077.9989  2078.0718   -35.07  106  -  124  2   E.EIGLVGVREMYKSLGTPVD.A + Oxidation (M) 
2143.0382 2142.0309  2141.9358   44.4  65  -  84  2   D.VVSPGGNAYGEEMTATCLRD.M + Oxidation (M) 
2154.0058 2152.9985  2152.9915   3.26  125  -  145  2   D.AVAQAVREMKAVATGMMSGDD.A + Oxidation (M) 
2257.1880 2256.1807  2255.9021   124  133  -  154  3   E.MKAVATGMMSGDDAAEAGAYFD.Y + 3 Oxidation (M) 
2457.2236 2456.2163  2456.0981   48.1  125  -  148  3   D.AVAQAVREMKAVATGMMSGDDAAE.A + 3 Oxidation (M) 
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Table 2.2. The mass spectrometry data for the sequences of the Methylenetetrahydrofolate-tRNA-(uracil-5-)-methyltransferase of Bacillus subtilis strain 168 that 
were identified by the MALDI for the GluC digest.  
Observed   Mr(expt) Mr(calc)    ppm   Start   End Miss   Peptide 
859.4105   858.4032   858.5215   -137.77  370  - 376  0   D.LLIFPKE.T 
971.4598   970.4526   970.5811   -132.42  424  - 431  1    E.RALEILKE.W 
983.4484   982.4411   982.3888   53.2  189  - 196  0    E.AYLNCPMD.Q 
989.4794   988.4721   988.5341   -62.77  212  - 219  1    E.RAPIKEFE.K 
1063.5159   1062.5086   1062.5134   -4.54  218  - 225  1    E.FEKQVHFE.G 
1355.6133   1354.6060   1354.5169   65.8  189  - 199  2    E.AYLNCPMDQDE.Y 
1370.7093   1369.7020   1369.7817   -58.15  129  - 142  0    E.KGIVIVASGPLTSE.S 
1399.6342   1398.6269   1398.7870   -114.47  424  - 434  2    E.RALEILKEWIE.K 
1535.8027   1534.7954   1534.8144   -12.35  290  - 302  1    E.QKRVFSFIPGLED.A 
1600.7476   1599.7403   1599.7893   -30.59  99  - 111  2    D.REGFSRYITETLE.D 
1735.8344   1734.8271   1734.8941   -38.59  290  - 304  2    E.QKRVFSFIPGLEDAE.F 
1752.8375   1751.8302   1751.7647   37.4  218  - 231  2    E.FEKQVHFEGCMPVE.V + Oxidation (M) 
1753.0750   1752.0677   1751.7647   173  218  - 231  2    E.FEKQVHFEGCMPVE.V + Oxidation (M) 
1774.8175   1773.8102   1773.8832   -41.13  174  - 188  1    D.MTKVFRASRYGKGEE.A + Oxidation (M) 
1926.0339   1925.0266   1925.0370   -5.41  113  - 128  3    D.HPLIDIHREEVTKIPE.K 
2168.0496   2167.0423   2167.1861   -66.35  417  - 434  3    E.RGRAQAERALEILKEWIE.K 
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2.3.2  ESI Results  
Due to the fact that the sequence coverage produced by MALDI analysis was only 35%, one aliquot 
from each of the digested samples was also used in ESI analysis of the Fc fragment.  The GluC digest 
identified a total of 23 peptide sequences of which nine of them were not assigned to any protein hits 
by the mascot server, this left 14 that were all associated with IgG Fc. Of these 14 peptides, six of 
them were found to be associated with IgG1 Fc, six were associated with IgG3 Fc and 2 were 
associated with IgG2 Fc. The sequence coverage for IgG1 was 27.6%, for IgG2 it was 32.3% and 
for IgG3 it was 28.7%. One of the identified peptides was also present within the sequence of IgG4 
Fc and gave a sequence coverage of 11.5% however it was not identified as being present in IgG4 
Fc by the server. This sequence was identified as being present in the amino acid sequence of IgG4-
Fc using the BLAST software on the NCBI server. Whilst there were 14 peptide hits, only 5 of these 
were unique peptide sequences. One of these sequences was identified by 8 of these hits, across all 
three of the identified subtypes (albeit with some differential oxidation). The second peptide 
accounted for a further three hits (being found in all three subtypes). The final three peptides were 
all only identified once each, with each one being unique to a different subtype. These sequences 
along with their corresponding data can be found in appendix 1. 
When the sequences obtained from all four of the digests between these two techniques were 
combined, the final overall sequence coverage for IgG1-Fc was 84.5% and all but four of the 
identifying residues (Tyr 291, Tyr296, Ala339 and Pro445) had been observed. The coverage for 
IgG2-Fc, IgG3-Fc and IgG4 was considerably lower, at 28.2%, 12.1% and 11.3% respectively. 
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Table 2.3. The mass spectrometry data for the sequences of the IgG1-Fc that were identified by ESI analysis of the sample of serum IgG-Fc that was disgested by 
GluC. The cut-off parameters were -200 ppm and a maximum number of two missed cleavages. The sample was purified using FPLC before being inserted 
into the ionisation chamber of the ESI machine. 
 
 
Query Observed Mr(expt) Mr(calc)  ppm   Miss Score Expect Rank Unique  Peptide 
3   792.7769   1583.5393 1583.7138 -110.16 1 67 8.2e-005 1       E.VTCVVVDVSHEDPE.V 
11   685.8033   2739.1842 2739.5033 -116.49 0 (99) 7.4e-008 1       E.LLGGPSVFLFPPKPKDTLMISRTPE.V 
12   914.0761   2739.2064 2739.5033 -108.41 0 158 8.1e-014 1       E.LLGGPSVFLFPPKPKDTLMISRTPE.V 
13   689.8008   2755.1740 2755.4983 -117.69 0 (78) 8.9e-006 1      
 E.LLGGPSVFLFPPKPKDTLMISRTPE.V + 
Oxidation (M) 
14   919.4057   2755.1952 2755.4983 -109.99 0 (130) 6.2e-011 1      
 E.LLGGPSVFLFPPKPKDTLMISRTPE.V + 
Oxidation (M) 
16   972.3779   2914.1119 2914.4245 -107.26 1 92 4.8e-007 1 U  E.MTKNQVSLTCLVKGFYPSDIAVEWE.S 
Chapter 2 
Page 64 of 141 
 
 
IGHG2      ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60 
IGHG3      ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60 
IGHG1      ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60 
5W5M       ------------------------------------------------------------ 0 
IGHG4      ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60 
                                                                        
 
IGHG2      GLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCC----------------- 103 
IGHG3      GLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSC 120 
IGHG1      GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE--------------------- 99 
5W5M       ------------------------------------------------------------ 0 
IGHG4      GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVE--------------------- 99 
                                                                        
 
IGHG2      ---------------------------------VECPPCPAPPV-AGPSVFLFPPKPKDT 129 
IGHG3      DTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDT 180 
IGHG1      --------------------------PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT 133 
5W5M       ----------------------------------TCPPCPAPEAAGASSVFLFPPKPKDT 26 
IGHG4      --------------------------SKY---GPPCPSCPAPEFLGGPSVFLFPPKPKDT 130 
                                              ** ****::::::************ 
 
IGHG2      LMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVH 189 
IGHG3      LMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLH 240 
IGHG1      LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH 193 
5W5M       LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH 86 
IGHG4      LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH 190 
           *****************:*****:*:*******************:***:********:* 
 
IGHG2      QDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVK 249 
IGHG3      QDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVK 300 
IGHG1      QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK 253 
5W5M       QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK 146 
IGHG4      QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK 250 
           ****************:**::*******:***************::*:************ 
 
IGHG2      GFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE 309 
IGHG3      GFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHE 360 
IGHG1      GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE 313 
5W5M       GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE 206 
IGHG4      GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE 310 
           *******:*****:*******:****:***********:*********:**:******** 
 
IGHG2      ALHNHYTQKSLSLSPGK 326 
IGHG3      ALHNRFTQKSLSLSPGK 377 
IGHG1      ALHNHYTQKSLSLSPGK 330 
5W5M       ALHNHYTQKSLSLSLGK 223 
IGHG4      ALHNHYTQKSLSLSLGK 327 
           ****::********:** 
Figure 2.4. The Sequence coverage of all of the IgG Fc subtypes produced by the MS/MS analysis of a 
GluC digest and a trypsin digest performed on the Purified human serum IgG Fc Fragment (P80-204). 
The matched peptides are shown in bold red, the highlighted green residues indicate the start point of the CH2 
domain and as a result the start of the Fc region. The * represents homologous residues within the sequences 
and : represents residues which are not homologous across the subtypes. 5W5M (Tam et al. 2017), was the 
structure that was used as the start point for the map analysis, the bold residues within this sequence indicate 
where its sequence differed from the sequences that were identified by the mass spectrometry analysis. The 
data for the sequences is located in Appendix 1. The sequences were obtained from UniProt and the alignment 
was produced using Clustal Ω. 
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2.4  Discussion 
The analysis of the sequence of the IgG-Fc isoforms within the protein sample by mass spectrometry 
was performed alongside the x-ray crystallographic analysis of the structure to aid in the correct 
identification of the isoform of IgG-Fc that was present in the protein crystals. Two samples 
produced by digestion with two different enzymes: trypsin and GluC, were used due to their different 
lysing patterns. Trypsin cleaves peptide bonds at the C-terminal of lysine and arginine residues and 
GluC, cleaves peptide bonds at the C-terminal of glutamic acid and aspartic acid residues. The 
differential lysing was important because it meant that they would produce different sequence 
fragments and as a result give better sequence coverage. This proved to be true as the two samples 
that ran on the ESI identified sequences that the other missed, which improved the sequence coverage 
from 65.3% that came from just the GluC digest to 84.5% across the two samples.  
Both ESI and MALDI were performed on both of the digest samples once again in order to improve 
the sequence coverage because the two techniques produce sequence fragments of different lengths 
with MALDI producing longer sequences than ESI mass spectrometry. This meant that there was a 
greater chance of producing a sequence with one of the techniques that the other failed to pick up on 
and as such they complement each other. This proved to be an effective technique due to the fact 
that the GluC sample, run on the MALDI failed to recognise any sequence fragments that were 
associated with IgG-Fc. As a result of this the MALDI produced a maximum of 35% sequence 
coverage for IgG1-Fc, which was not high enough to confirm the sequence. Once the ESI analysis 
was performed this improved the sequence coverage to 84.5%. However, the 49.5% sequence 
coverage produced by ESI was not enough to conclusively identify the sequence of any of the IgG 
subtypes that were in the sample. Because of this it was required to combine the results of both of 
the mass spectrometry techniques in order to gain enough information on the sequences to be able 
to definitively say which of the sequences are present in the sample. 
The mass spectrometry proved to be an effective companion technique to the x-ray diffraction 
analysis of the protein structure. This was due to the fact that determining the sequences of the IgG-
Fc isoforms IgG1-Fc, IgG2-Fc and IgG3-Fc within the sample, meant that the potential IgG-Fc 
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sequences were known and such made fitting the backbone into the electron density easier and made 
determining which isoform was in the structure more accurate. The accuracy of the mass 
spectrometry analysis can further be confirmed by the relative proportions of the sequences that were 
identified. The largest proportion of the sequences that it identified were from IgG1-Fc (84.5%), 
with lower sequence coverage for IgG2-Fc (28.2%) and IgG3-Fc (12.1%). These values reflected 
the reported abundances of the IgG isoforms in human serum: 60% IgG1, 32% IgG2, 4% IgG3 and 
4% IgG4. 
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Chapter 3 – Protein Crystallisation and Structure Determination 
3.1  Introduction 
3.1.1  An Introduction to X-ray Crystallography 
X-ray crystallography is the most direct method of producing models of macromolecules such as 
proteins. It was discovered in the early 19th century and saw huge development throughout the 19th 
and 20th centuries (Hunefeld, 1840). Crystallographers have produced thousands of three 
dimensional images of macromolecules, these images have provided detailed information on the 
activity of these macromolecules as well as their binding mechanisms as well as any conformational 
changes they may undergo (McPherson 1991, 1999).  
Protein crystallography is a technique used to produce magnified images of proteins using x-rays 
instead of a traditional lens (Drenth, 1994). This due to the need to use light with a wavelength of no 
longer than 3.5 Å in order to be able to image the atomic structure of macromolecules (Helliwell, 
1984). This is because covalent bonds between atoms are between 1-2Å and strong polar interactions 
are between 2.5-3.5Å (Cornilescu, G et al, 1999), hence visible light would not be able to image the 
atomic structure as its wavelength is between 350 nm and 750 nm (Drenth, 1994; Engh & Huber, 
1991).  
In a laboratory setting X-rays are produced in a vacuum by focusing a beam of electrons at a metal 
target, in order to do this the potential difference between the cathode which releases the electrons 
and the target must be in the order of 10s of kilovolts (Hammond, 1997; Gruner, 1994). This potential 
difference needs to be so great in order for the electrons to possess enough energy so that when they 
strike the target enough energy is transferred to cause the electrons within the metal atoms to 
transition to a higher energy state and release photons (X-rays) (Ladd & Palmer, 1993). The X-rays 
produced by this method have wavelengths of between 0.5 Å and 1.6 Å. These X-rays have 
wavelengths that are just shorter than the ‘soft’ X-ray region and as a result they penetrate biological 
materials enough to be scattered by the entire volume of any target crystals (Miyahara et al, 1986).  
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3.1.2  X-ray detectors and Sources 
In X-ray crystallography the scattering by the crystal can be viewed from all possible directions, this 
is because the X-ray beam is incident from as many directions as possible, and as much of the 
scattered radiation as possible is recorded (Smyth & Martin, 2000). Because of the way that this data 
is collected, the images which result from crystallographic studies are 3-dimensional (Als-Nielsen 
& McMorrow, 2001).  
X-ray detectors are devices that react to the intensity of X-ray beams that they are exposed to (Gruner 
et al, 1994). At a given wavelength, the intensity of the X-ray beam measured by these detectors is 
a direct measure of the number of photons the beam delivers. The classical X-ray detectors were 
sheets of photographic film. In which silver iodide crystals absorb X-ray photons when exposed to 
an X-ray beam (Su & Zang, 2014; Wiechenberger & Pozharski, 2013). This absorption releases 
enough energy to create an imperfection in the crystal lattice of the film; allowing a diffraction image 
to be built up. When the image is being developed these imperfections allow the silver iodide to be 
reduced to silver which causes the emulsion on the film to blacken producing spots. These spots are 
then used to build up the diffraction image (Su & Zang, 2014).  
More modern detectors utilize the ionisation of gases, caused by X-rays passing through them to 
create a current which the detector can interpret (Als-Nielsen & McMorrow, 2001). The intensity of 
the X-ray is proportional to the rate at which this current is transmitted. In order to detect the X-ray 
scattering using this type of detector, an absorber with a small central hole is required (Gruner, 1994). 
However as the scattering can only be detected when X-rays strike this central hole, this type of 
detector can only observe diffraction one point at a time. Because no X-ray lenses have been 
discovered, modern X-ray detectors are required to perform computational transformations to mimic 
the glass lens of a microscope and ‘view’ the diffraction image (Drenth, 1994).  
Diffractometers are instruments which manipulate the orientation of protein crystals as well as the 
detector position; all while keeping the crystal in an X-ray beam. However; because they measure 
electron energies sequentially, they are slow when experimenting with large crystals. Additionally, 
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they can also only be used in non-biological studies due to the complexity of the diffraction patterns 
that biological compounds produce (Bukowska & Gru, 2013). 
In the time since the 1990s, many position sensitive detectors have been developed. These detectors 
are as accurate as counters but can view much larger areas of the sample, making them more effective 
(Gruner, 1994; Rhodes, 2000). The most widely used position sensitive detector is the image plate, 
in which the diffraction image is created when atoms within the plate are promoted to a higher energy 
state when they are struck by photons during exposure to an x-ray source. The images produced in 
this way are “read” by scanning a beam of light across the plate which causes the excited atoms to 
fluoresce. The intensity of this fluorescence is proportional to the total energy of the x-rays which 
struck the plate. It is this fluorescence which is used to build the image. The stored image can then 
be erased by “flooding” the plate with light, allowing the plates to be reused. However much like the 
photographic film, this method does not record the time of flight of the X-rays and a separate method 
is required in order to record the image (Rhodes, 2000; Su et al, 2014).  
3.1.3  A Brief Overview of Macromolecular Crystal Point Groups 
Many protein molecules are made up of multiple identical peptide chains in symmetrical 
arrangements. Proteins usually have the same number of symmetry operations as chains; e.g. dimers 
have 2-fold symmetry and trimers have 3 fold symmetry (Mazey 1990). Tetramers tend to have 2-
fold symmetry around each of the 3 perpendicular directions (within 3-dimentional space). This is 
referred to as 222 symmetry, due to the 3, 2-fold axes (Holser, 1958). Due to the constraints of the 
crystal lattice, protein crystals can only have 2, 3, 4 or 6-fold symmetries limiting the number of 
possible point groups to 11 (International Union of Crystallography, 1995).  
The final type of point group is the cubic point group. These have 3-fold symmetry and can be 
observed by visualising the crystal in the corner of a cube. Cubic point groups have 3 fold axes in 4 
cardinal directions (Holser, 1958). The most simple cubic point group (23) also has 2-fold axes in 3 
perpendicular directions. Another more complicated example (432) contains 4-fold axes in these 
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directions as well as 2-fold axes at 45° to these 4-fold axes (International Union of Crystallography, 
1995).  
3.1.4  An Introduction to Bragg’s Law and Macromolecular Crystal Space-Groups 
Bragg’s law is a physical principal which predicts the angle of reflection for a diffracted beam, which 
has been diffracted by specific atomic planes and is defined by the following equation:.  
2𝑑 𝑠𝑖𝑛𝜃 = 𝑛𝜆 
This equation applies when the interplanar spacing of the planes, the wavelength of the incidence 
beam and the order of reflection are known (Bragg, 1975). 
Bragg’s law can also be defined using Laue equations, which define the following set of conditions 
under which diffraction occurs:  
𝑎 ∙ 𝑆 = ℎ 
𝑏 ∙ 𝑆 = 𝑘 
𝑐 ∙ 𝑆 = 𝑙 
Where h, k, l are the Miller indices; a set of values that define a unique plane of reflection, a, b and 
c are the lattice vectors and S is the difference between the incidence and reflected vectors for the 
hkl plane (Helliwell, 1984) 
The unit cell of a crystal can be described as a cube whose boundaries correspond to the 3 lattice 
translations: a, b and c, with angles between the translations of α, β and γ (Als-Nielsen & McMorrow, 
2001). These lattice translations describe both the length and direction of the boundaries of the unit 
cell and whilst they can be a range of lengths and angles, they are restricted in what these can be 
(Helliwell, 1984). The convention is to describe the unit cell by the smallest possible volume that 
can create an entire crystal lattice using only symmetry operations. These are referred to as primitive 
unit cells and are described by primitive lattice translations. The position of a body within a unit cell 
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is defined by the values x, y and z, these values represent the distances along the three axial directions 
(Bragg 1975; Helliwell, 1984; Als-Nielsen & McMorrow, 2001).  
While crystal lattices can freely have translational symmetry; rotational symmetry places restrictions 
on the shape of the unit cell of a crystal. This is because the unit cells must stack so they fill of the 
space within the crystal, whilst also fulfilling the symmetry. This means that in order to have 2-fold 
symmetry, the unit cell must have two lattice translations that are perpendicular to the fold axis. For 
example; if the fold axis is in the b direction, then there must be a lattice translation in the a and c 
directions. In the case of 3-fold, 4-fold and 6-fold symmetries one of the lattice translations must be 
parallel to the fold axis, whilst the other two must be perpendicular to the fold axis e.g. if the fold 
axis is in the c direction then one lattice translation must also be in the c direction and the other two 
must be in the a and b directions (Bragg 1975; Helliwell, 1984; Als-Nielsen & McMorrow, 2001).  
The space group of a crystal is the complete set of symmetry operations that make up a three-
dimensional lattice and define its shape. The smallest unit of a crystal that can generate a complete 
crystal structure is called the asymmetrical unit, it is called this as it does not have or require any 
symmetry operations (Wukovitz & Yeates, 1995; Ramakumar & Viswamitra, 1990).  
The P1 space group is the simplest as it has no symmetry except the lattice translations, the P 
indicates that the unit cell is primitive rather than face of body centred and that the highest rotational 
symmetry is 1-fold (International Union of Crystallography, 1995; Leslie, 2000). It has been 
demonstrated that if a tetrameric molecule has two perpendicular 2-fold axes, then it must also have 
a third 2-fold axis which is perpendicular to the other two (Mighell, et al, 1983). This observation 
also applies to lattices. This is because the axis directions (a, b, c) are assigned as the lattice 
dimensions; this means that any lattice which has three perpendicular 2-fold axes must be 
rectangular/ orthorhombic in shape. The most simple orthorhombic space group is the 222 space 
group, in this space group all three of the 2-fold axes intersect at the origin (Wukovitz & Yeates, 
1995).  
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The P222 space group is a primitive space group with three intersecting 2-fold axes. This produces 
four different positions within the unit cell which means that the lattice can be built up to produce a 
tetramer at every lattice point. The P212121 space group is very similar to the P222 space group 
however the three 2-fold axes are replaced by 2-fold screw axes; these are axes that rotate by 180° 
like a 2-fold axis but also shift half a cell length in the direction of the axis. These screw axis copy 
lattice features at (0, y, 0), (x, 0, 0) and (0, 0, z) to (-x, y+1/2, -x), (x+1/2, -y, -z) and (-x, -y, z+1/2) 
respectively (Als-Nielsen & McMorrow, 2001).  
3.1.5  Diffraction by Macromolecular Crystals 
In diffraction by a 3-dimensional, repetitive object like a protein crystal the incident rays are 
scattered in many different directions (Giacovazzo et al. 1992; Hammond, 1997). This means that 
whilst all of the unit cells cause the beam to scatter diffraction will only occur if all of the scattered 
rays are in phase. This is because the scattered rays will experience destructive interference if they 
are out of phase with the other rays that they interact with. In a crystal it is only possible for all the 
rays to be in phase with each other if the crystal is aligned correctly within the incident beam (Gruner, 
1994; Hammond, 1997). 
Fourier transformation analysis is a process where a series of waves are represented as their sum. 
This type of analysis is utilised in crystallography to analyse the repetitive structures within the 
crystal (Als-Nielsen & McMorrow, 2001). Fourier transformations are performed by determining 
the amplitude of the Fourier components of each individual structure from the variance of the 
electron density that the structures produces (Drenth, 1994). The inverse Fourier transform, is 
performed by using the amplitudes and phases of the waves to calculate the density of electrons 
within the crystal (Als-Nielsen & McMorrow, 2001). In structural studies of three-dimensional 
objects such as crystals, the object of interest needs to be rotated in order to build up the full image 
of the structure. This is because the object would only produce a 2-dimensional image if it was shot 
from one direction only (Hammond, 1997). 
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Due to their high solvent content (often as high as 50%) (McPherson & Gavira, 2014), crystals will 
only diffract to a limited resolution which is often between 3.0Å and 2.0 Å (Helliwell, 1984). The 
lower the solvent content of the crystal (and hence the higher protein content), the higher this 
resolution limit is (Okada et al, 2002; Mathews, 1968).  
Protein crystals represent proteins in their most highly ordered form, it is this order that allows the 
protein molecules to be imaged (Hammond, 1997; McPherson, 1991). This is because all of the 
protein molecules within a crystal are identical, and in identical environments. Protein crystals are 
organised in such a way that each and every protein interacts with it neighbouring proteins in exactly 
the same way (Phillips et al. 1976). Each repeating unit inside a crystal is in an identical environment 
to all the other repeating units within said crystal. The way that these repeating units fit together 
causes the crystals to have flat faces and sharp edges (Rhodes, 2000; Wlodawer et al. 2013).  
 
Crystals will only grow if the mother liquor that surrounds them is supersaturated; being polyions, 
the solubility of proteins is directly affected by the concentration of surrounding ions (Wlodawer et 
al. 2013). The presence of ionic compounds; or compounds that sequester water such as Polyethylene 
glycol 4000 (PEG), reduces protein solubility and therefore favours crystal growth (McPherson 
1999; Ewald, 1963; Richmond et al. 1997). As a protein crystal grows, larger numbers of protein 
molecules are deposited on the surface of the crystal in an orientation that allows the pattern of 
crystal growth to continue. In an ideal scenario, if the protein was incorrectly oriented it would 
immediately dissociate from the lattice before any interactions are formed (Rhodes, 2000). However, 
this is not always the case and growth which continues in this vain often leads to imperfections 
within the lattice. Due to the irregular size of macromolecular crystals, the protein molecules cannot 
pack as tightly together and fill all of the space within the crystal. These voids are then filled by the 
mother liquor, usually in aqueous form. The ingress of the mother liquor results in the crystal 
becoming fragile with impurities getting trapped within it (McPherson, 1991; 1999; Rhodes, 2000).  
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3.2  Methods 
Dried native human IgG Fc fragment (Bethyl laboratories) was reconstituted using 200 µl filtered, 
deionised water before being dialysed into 50 mM sodium acetate pH 4.5. The solution was 
concentrated up with a vivaspin 500 spin column to a concentration of 10 mg/ml.    
Hampton crystallisation screen 2 performed on 8 mg/ml IgG Fc fragment A modified condition F10 
(16% PEG 2K instead of 10K) was chosen to be the basis for a series of screens used to solve the 
structure of the native Fc fragment.  
The Dp12 (degree of polymerisation) heparin was produced and dried by the Skidmore research 
group, before being made up to a final concentration of 10 mM in filtered deionised water.  
Once the native structure of the Fc fragment was solved, a batch of recombinant Fc fragment (Cat: 
10702-HNAH) was purchased from Sino Biological. This second protein was reconstituted in 
filtered deionised water before being buffer exchanged and concentrated up using a Vivaspin500 
centrifuge column on a being spun at 13000 rpm.  
3.2.1  Materials 
3.2.1.1  Preparation of IgG–Fc from Sera 
Dried native human IgG Fc fragment (Bethyl laboratories) was reconstituted using 200 µl filtered, 
deionised water before being dialysed into 50 mM sodium acetate pH 4.5. The solution was 
concentrated up with a Vivaspin 500 spin column to a concentration of 10 mg/ml, the concentration 
of the stock solution was monitored using a Nanodrop machine at 260/280 nm. The final 
concentration was obtained from the extinction coefficient that was calculated to be 1.365 by the 
Protparam program. This protein was used in crystallisation experiments which are detailed below. 
Due to the small volume of stock that was left after it was concentrated down, the stock was then 
further diluted to 8 mg/ml in order to maximise the number of wells which could be set down. 
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3.2.1.2  Preparation of Recombinant IgG–Fc 
A batch of recombinant IgG–Fc fragment (Cat: 10702-HNAH) was purchased from Sino Biological. 
This protein was reconstituted in 1 ml of filtered deionised water to a concentration of 0.2 mg/ml 
before being buffer exchanged and concentrated up using a Vivaspin500 centrifuge column being 
spun at 13000 rpm for 12 minutes. The sample needed to be concentrated up a further two timesin 
order to get the solution to the minimum required concentration of 8 mg/ml. The concentration of 
the protein solution was monitored with a Nanodrop at 260/280 and the final concentration was 
obtained from the extinction coefficient that was also calculated to be 1.365 by the Protparam 
program.  
3.2.1.3  Preparation of Heparin Ligands 
The dp12 (degree of polymerisation) heparin fraction was produced, purified and dried by the 
Skidmore research group, before being made up to a final concentration of 10 mM in filtered 
deionised water. A second rough heparin fraction (mr 5.5 KDa ± 550 Da) was also produced and 
provided by the Skidmore research group. Finally, this fraction was taken and made up to a final 
concentration of 95 mM for use in crystallisation experiments. 
3.2.2  Crystallisation of Native IgG-Fc From human sera 
Crystallisation conditions based on previous work, both published and performed in-house were 
performed for the Fc fragment. The starting condition for these crystallisation trials were: 18% PEG 
3350 and 0.1M MES pH 6. The suitable well conditions for the Fc region at 8mg/ml produced by 
these screens after optimisation were 0.1M MES pH 6.3, 18% PEG 3350 and 50 mM sodium acetate 
pH 4.5. Two crystal forms were produced by these conditions: short, wide rods which sometimes 
had pointed ends or a shower of small jagged crystals. These wells were cryoprotected by adding six 
lots of 2µl of glycerol aliquots to the well. These aliquots increased in concentration from 5%-30% 
glycerol. Once the 30% aliquot was added to the well, 12 µl of the mother liquor were exchanged 
with 12 µl of 30% glycerol to give a final glycerol concentration of 25%. The crystals were then 
frozen by submersion in liquid nitrogen. In total, eleven crystals were collected from a single well 
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(HE2A2). After four crystals had been collected, 2 µl of the 10 mM dp12 solution was added to the 
well and was left to soak for a further ten minutes. 
3.2.3  Data Collection, Processing and Refinement of the Native Structure of IgG Fc 
Data collection of the structure of IgG-Fc was carried out on beamline I04 at the Diamond Light 
Source (Oxford, England) at a wavelength of 1.000 A
ͦ
 and a temperature of 100 K. The diffraction 
images were processed using the MOSFLM program, the data was then merged and scaled using the 
AIMLESS program (Evans, 2006; Evans 2011) and averaged using the TRUNCATE program. The 
crystallographic model was produced and refined by the REFMAC program (Murshudov, 2011) and 
improved using molecular replacement within the COOT program (Emsley, 2010) using the 
coordinates of the structure of the IgG Fc region (PDB code 5W5M). This reference structure had 
the N-linked glycosylation at Asn297 as well as the water molecules removed from it in order to 
prevent bias from being introduced to the density.  
3.2.3.1  Data processing and refinement of the Native Structure of IgG Fc 
Fifteen datasets were collected from a total of 4 native and 7 dp12 soaked crystals of IgG Fc purified 
from human sera. Of these fifteen datasets, only two of them, one produced by a native crystal 
HE2A21 and one by a dp12 soaked crystal HE2A29 produced high resolution data. The diffraction 
images of HE2A21 were indexed into the primitive orthorhombic space group P21 21 21 by 
MOSFLM with unit cell parameters of: 
a = 49.76 b = 79.46 c = 139.71       α = 90.0° β = 90.0° γ = 90.0° 
Once the images had been integrated by the MOSFLM program. The data was then scaled and 
merged at a resolution of 2.30 A
ͦ
 which gave Rmerge statistics of 0.072 and 0.368 in the outershell. 
The overall I/σ and CC1/2 values for the dataset were 13.8 (3.9 in the outershell) and 0.998 (0.923 
in the outershell) and a completeness of 99.9% overall and 100.0% in the outershell. In Truncate an 
L-test was performed to determine whether or not the data was twinned. The twinning analysis 
determined that the data was untwinned. 
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The diffraction images from HE2A29 were also indexed into the primitive orthorhombic spacegroup 
P21 21 21 with a unit cell of: 
a = 49.667 b = 79.599 c = 138.002       α = 90.0° β = 90.0° γ = 90.0° 
Once the images had been integrated by the MOSFLM program, they were scaled and merged using 
the Pointless-Aimless pipeline which also determined the unit cell parameters alongside the 
spacegroup. The data was scaled and merged at a resolution of 2.15 A
ͦ
 which gave Rmerge statistics 
of 0.064 and 0.397 in the outershell. The overall I/σ and CC1/2 values for the dataset were 12.6 (3.6 
in the outershell) and 0.997 (0.795 in the outershell) and a completeness of 99.7% overall and 99.8% 
in the outershell. The structure factors were produced by Truncate and an L-test was performed to 
determine whether or not the data was twinned. The twinning analysis determined that the data was 
untwinned. 
From these datasets the supposedly ligand bound data of HE2_A29 was chosen to be taken forward 
for structural analysis due to it being higher resolution. 
3.2.3  Protein Crystallisation Trials of a Heparin Soaked Recombinant IgG1-Fc 
Fragment 
The conditions set down in the dp ligand soak trials were based on the conditions set down during 
the native structure screen, which successfully produced the high resolution structure (HE2A2). The 
conditions set down were: 18% to 20% PEG 3350 and 0.1M MES pH 6.1 to pH 6.5. These wells 
contained the same 8mg/ml sample dried, native human IgG Fc that was used in the native structure 
screen.  
A second set of conditions, all based off HE2A2 were set down, however the protein used in these 
trials was the recombinant human IgG1 Fc.   
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3.2.4  Ligand Soaking Trials of the Recombinant IgG1-Fc Fragment with a Rough 
Heparin Fraction 
In the first round of soaking trials 2 µl of the 10 mM dp12 ligand was soaked into the well after 
cryoprotection with 30% glycerol and exchange. The crystals were then left for 10 minutes before 
crystals were retrieved and frozen.  
The second round of soaking trials were conducted using the longer heparin fraction. During these 
trials two 0.5 µl additions of the heparin were added to the well, after which 0.1 µl of 1.55 M pH 4.5 
sodium acetate was added to the well. This was done to emulate the conditions used within the 
circular dichroism experiment where the change in IgG-Fc in the presence of heparin was noted 
(Hadfield, 2018; A shrive 2017, personal communication, 15 November). This reduced the 
concentration of heparin in the well to 30.7 mM and the protein to 0.05 mM.  
3.2.5  Data Collection, Processing and Refinement of the Heparin Soaked Structure of 
IgG Fc 
Data collection of the structure of heparin soaked IgG-Fc was carried out on beamline I04 at the 
Diamond Light Source (Oxford, England) at a wavelength of 1.000 A
ͦ
 and a temperature of 100 K. 
The diffraction images were processed using the MOSFLM program, the data was then merged and 
scaled using the AIMLESS program (Evans, 2006; Evans 2011) and averaged using the 
TRUNCATE program. The structure produced by crystal HE2 A29 was used as a starting model and 
the structure was refined by the REFMAC program (Murshudov, 2011) with alternating cycles of 
model fitting with the COOT program (Emsley, 2010) . This reference structure had the N-linked 
glycosylation at Asn297 as well as the water molecules removed from it in order to prevent bias 
from being introduced to the density.  
Four datasets were collected from a total of nine heparin soaked crystals of recombinant IgG Fc. Of 
these four datasets, only two of them (HE4 C18 and HE4 C19), produced any data. The diffraction 
images of HE4 C18 were indexed into the primitive orthorhombic space group P21 21 21 by 
MOSFLM with unit cell parameters of: 
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a = 49.76 b = 79.46 c = 139.71       α = 90.0° β = 90.0° γ = 90.0° 
Once the images had been integrated by the MOSFLM program, they were scaled and merged using 
the Pointless-Aimless pipeline which also determined the unit cell parameters alongside the 
spacegroup. The data was scaled and merged at a resolution of 3.55 A
ͦ
 which gave Rmerge statistics 
of 0.118 and 0.429 in the outershell. The overall I/σ and CC1/2 values for the dataset were 10.7 (4.7 
in the outershell) and 0.980 (0.540 in the outershell) and a completeness of 95.3% overall and 89.9% 
in the outershell. The structure factors were produced by Truncate and an L-test was performed to 
determine whether or not the data was twinned. The twinning analysis determined that the data was 
untwinned. 
The diffraction images from HE2A29 were also indexed into the primitive orthorhombic spacegroup 
P21 21 21 with a unit cell of: 
a = 49.667 b = 79.599 c = 138.002       α = 90.0° β = 90.0° γ = 90.0° 
Once the images had been integrated by the MOSFLM program, they were scaled and merged using 
the Pointless-Aimless pipeline which also determined the unit cell parameters alongside the 
spacegroup. The data was scaled and merged at a resolution of 3.60 A
ͦ
 which gave Rmerge statistics 
of 0.118 and 0.430 in the outershell. The overall I/σ and CC1/2 values for the dataset were 11.0 (4.8 
in the outershell) and 0.979 (0.520 in the outershell) and a completeness of 95.1% overall and 79.4% 
in the outershell. The structure factors were produced by Truncate and an L-test was performed to 
determine whether or not the data was twinned. The twinning analysis determined that the data was 
untwinned. 
3.3  Results 
3.3.1  Results of the crystallisation trials 
Several crystallisation conditions for IgG-Fc purified from sera were put down. The well conditions 
were based on a previously established condition (18% PEG 3350 and 0.1M MES pH 6.5) which 
had produced a shower of small rod like crystals which had sharp pointed ends. This condition was 
then further optimised with two screens around this condition the conditions in this screen ranged 
from 16% - 20% PEG 3350 and 0.1M MES pH6.1 to pH6.7. These conditions produced several 
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crystal forms, the main form was a shower of small rod like crystals either with or without the same 
pointed tips seen in the initial condition. The second most common form was larger rods with flat 
tips. 
3.3.2  Structure determination of Native IgG-Fc 
Crystals from several wells were cryoprotected with 30% glycerol and used in diffraction 
experiments. Fifteen datasets produced by these X-ray diffraction experiments of IgG-Fc crystals 
were produced. Five of these datasets were produced by native IgG-Fc crystals, with the remaining 
ten datasets being produced by dp12 soaked crystals of IgG Fc purified from human sera. The data 
was collected at Diamond Light Source by the protein crystallography research group, before being 
processed using programs from the CCP4i software suite (Winn, 2011). 
3.3.2.1  Data Processing and Selection 
The datasets were integrated and refined by the MOSFLM program; after which they were scaled 
and merged into an average intensity using the Pointless-Aimless pipeline which also determined 
the unit cell parameters alongside the spacegroup. Of the original fifteen datasets only two of them 
were chosen to be further processed: one produced by a native crystal HE2A21 and one by a dp12 
soaked crystal HE2A29, were further processed using the Truncate program. The details of the 
processed data statistics for the two datasets are included in table 1. The remaining thirteen datasets 
were not taken forward due to the data being of worse quality, in all cases the resolution was lower 
than the chosen datasets and the Rmerge values were greater, meaning that the data had not merged as 
well. From these datasets the ligand soaked data of HE2 A29 was chosen to be taken forward for 
structural analysis due to it being higher resolution. In the case of the four native datasets that were 
not chosen, they were all at a lower resolution than the chosen dataset (2.35A
ͦ
 - 2.85 A
ͦ
) and all of 
them had a much higher Rmerge than the chosen dataset (0.087 – 0.202 overall). As Rmerge is a measure 
of how well the data merges with a lower Rmerge value indicating higher quality data.  
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In the case of the nine dp12 soaked datasets that were not used all of them were at a much lower 
resolution than the chosen dataset (2.20 A
ͦ
 - 2.70 A
ͦ
) and all of them had worse overall Rmerge values 
(0.69 – 0.145). 
Table 3.1 – Initial Data Processing of the IgG1-Fc Purified from Sera Datasets.  
 Native IgG-
Fc purified 
from sera 
(HE2A21) 
Native heparin soaked 
IgG-Fc Purified from sera 
(HE2A29) 
Data Collection   
Synchrotron Station I04 I04 
Wavelength (Å) 0.9795 0.9795 
Space Group P 21 21 21  P 21 21 21  
Cell Dimensions (Å) a = 49.760 
b = 79.460 
c = 139.715       
a = 49.667  
b = 79.599  
c = 138.002        
   
   
Resolution Range 
(Å) 
79.46 – 2.30 
(2.16 – 2.30) 
69.00 – 2.15 
(2.21 – 2.15) 
Observations 465147 540415 
Unique Reflections 76108 98176 
Completeness (%) 99.9 (100.0) 99.7 (99.8) 
Rmerge  0.072 (0.368) 0.064 (0.397) 
CC1/2 0.998 (0.923) 0.997 (0.795) 
Mean (I/σ(I)) 13.8 (3.9) 12.6 (3.6) 
   
Refinement   
Protein Atoms 7008 7008 
Residues (Chain A) 208 207 
Residues (Chain B) 208 208 
Water Molecules 0 150 
   
Rwork (%) 0.2960 0.2493 
Rfree (%) 0.3558 0.3007 
Figures in parentheses refer to the highest resolution bin.  
a Rmerge = ΣhΣj | Ih,j – Ih | / ΣhΣj | Ih,j|, where Ih,j is the jth observation of reflection h and Ih is the mean of the j measurements of 
reflection h.  
b Rwork = Σh | |Foh| - |Fch| | / Σh |Foh|, where Foh and Fch are the observed and calculated structure factor amplitudes, respectively, 
for reflection h.  
c Rfree is equivalent to Rwork for a randomly selected subset (5%) of reflections not used in the refinement. 
d Determined according to MolProbity. 
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3.3.2.2  Density Map Generation and Analysis of Native IgG Fc 
The initial density maps for the native structure of the Fc region were produced following rigid body 
refinement (Refmac5), using native IgG4 Fc (5W5M PDB accession code) as a starting model. Only 
the protein components of this structure were used for this in order to prevent any bias being 
introduced into the map by the glycosylation and water. The initial rigid body maps before any model 
fitting for the Asn297 glycosylation site residue can be seen in figure 3.1. 
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Figure 3.1 – A comparison of the A and B chains in human IgG1-Fc before and after model fitting. A: 
The electron density of the Asn297 residue of the A chain before and after any fitting had taken place, the 
observed electron density map is at 1.0σ (blue) and the difference map (green [positive density] and red 
[negative density]) shows areas of positive and negative density and is at 3.0σ. Asn297 was 6.26 A
ͦ
 away from 
its final position.  B: The electron density of the Asn297 residue of the A chain before and after any fitting had 
taken place. In this chain Asn297 was not shifted over from its final position. The chain before fitting is shown 
in brown and the chain after fitting is shown in blue. 
The electron density for the Ala237 – Thr250, Val259 – 306 and Lys326 – Lys337 loops of the CH2 
domains, indicated that the CH2 domains of both of the A and B chains of the reported structure 
A 
B 
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were shifted away from their corresponding positions in the reference model (5W5M). The 
movement of the loops in the CH2 domains varied depending on where the residue was located 
within the chain with the greatest shifts being seen in the residues which were located closer to the 
hinge region some examples of these shifted residues are: Ala237 which was 6.66 A
ͦ
 from its 
corresponding residue, Glu269 which experienced a 6.87 A
ͦ
 and Phe296 which was shifted 6.98 A
ͦ
. 
The shift was greatly reduced in the residues closer to the CH3 domain, with the structures fully 
superimposing at residue 338 in both the A and B chains. The largest shifts in the structure were 
between Ala237 – Thr250, Val259 – 306 and Lys326 – Lys337 and can be seen in figure 3.2.   
 
Figure 3.2 – The shift in the CH2 domains of native IgG1-Fc and the reported structure of IgG1-Fc. A: 
The shift across the whole of the Fc region. The two structures superimpose after Lys338. B: the shift across 
residues Lys326 – Ser330 of the B chain. It is this loop which sees the greatest difference between the two 
structures. C: The shift at Glu269 of the B chain. D: The shift at Asn297 of the A chain.  The reference structure 
before any fitting is shown in cream and the final structure after fitting is shown in blue. 
A B 
C D 
Chapter 3 
Page 85 of 141 
 
In the initial structure of the N-termini, there was only clearly defined density visible for Gly237 in 
the A chain (Gly237A) and Gly236 in the B chain (Gly236B) onwards. There was some density 
visible for the residues which precede Gly237A and Gly236B which indicated that they were present, 
however the density was poorly defined and as such could not be modelled with confidence. This 
lack of defined density is most likely caused by the hinge region being cut with papain which allowed 
the N-termini to move around as they were no longer held in place by the hinge and CH1 
domains.This lack of definition within the N-terminus is found within several other native structures 
of IgG Fc, one example of this is the structure for a native IgG3 Fc region (5W38) which only had 
defined density for Lys235 onwards, another example is the structure of human IgG1 Fc (PDB code 
5JII) which also only had well defined density for Gly237 onwards so this lack of density in the N-
terminal appears to be a regular occurrence in structures of IgG-Fc.   
The N-linked glycosylation at Asn297 was clearly visible in the density of the 2Fo–fc (difference) 
map, which showed very positive density for both of the glycan chains. The glycans were modelled 
using the glycan add-on in the COOT program, using the complex hybrid mammal tree to build the 
two glycans into the density. The density for the entirety of the A chain glycan was very clearly 
defined and so it was very easy to model and fit into the density.  Both a core fucose and a 6’ 
galactose on the α1-6 arm of the glycan were visible in the A chain although no density for a bisecting 
N-Acetylglucosamine (GlcNAc) or terminal sialylation was observed for either of the glycan chains. 
The lack of density for these monomers implies that the the glycoform of IgG present in this structure 
was G1F, (where G refers to galactose and F refers to fucose) which makes up 38% of the glycoforms 
found within human serum. However it is also possible that the IgG-Fc sample used is of a different 
glycoform and that these monomers are simply not visible in the density. The structure of the glycan 
as well as the structure of the fitted glycan are shown in figure 3.3 and figure 3.4 respectively. 
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Figure 3.3 – The ASN297 N–Linked glycan of the sample of IgG-Fc purified from Sera. The association 
occurs through the GlcNAc at position 1 in the chain; with the GlcNAc at position 5 forming hydrogen bonds 
with the correlating GlcNAc of the N-linked glycan of the B chain. This hydrogen bond is the only major 
interaction between the two chains of the Fc fragment. 
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Figure 3.4 – The structure of the fitted N-linked glycan of IgG1-Fc bound to Asn297. A: The rigid body 
electron density map for the N-linked glycan before any fitting has been performed, the observed electron 
density map is at 1.0σ (blue) and the difference map is at 3.0σ. The structure is shown to elucidate on how the 
glycan sits within the protein chains. B: The electron density map of the N-linked glycan after 5 rounds of 
restrained refinement. The glycan of the A chain is shown in orange and the glycan of the B chain is shown in 
green. The reference structure before any fitting is shown in cream and the final structure after fitting is shown 
in blue.
A 
B 
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The density for the fucose of the B chain bound glycan was much weaker than the density for the 
rest of the glycan, and as a result there was not enough density visible to confidently model it. There 
was not enough density for the 6’ galactose visible in the B chain to fit it however it is still present 
in the glycan chain because the two glycans must be identical to each other. Once the glycans had 
been modelled and further refined the glycan statistics were run through the glycan validation 
program of the CCP4i suite, Privateer (Agirre et al. 2015), in order to determine whether the glycan 
model that had been produced had correct conformations and was not puckered. The Privateer output 
showed that the majority of the glycan residues were in favourable conformations. However the N-
linked GlcNAc1 in the glycan of the A chain was found to be very slightly enveloped, which is a 
thermodynamically unfavourable conformation due to the ring being puckered. However the 
conformation of the ring could not be altered in COOT without causing the rest of the residues to 
enter unfavourable conformations and after further rounds of refinement and fitting it was 
determined to be acceptable. The final fitted structure for the native Fc region of IgG1 that was 
produced from HE2 A29 is shown in figure 3.5.  
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Figure 3.5 – The proposed structure of Native IgG1-Fc produced in this report. The N-linked glycan is 
shown in Glycoblocks form, the waters are shown as red spheres. 
3.3.3  Structural Work for IgG-Fc Soaked with a Rough Heparin Fraction 
3.3.3.1  Ligand Soak Trials 
In order to produce a structure for heparin bound IgG-Fc a different ligand soaking strategy was 
produced in order to increase the molar fold difference between the heparin and the IgG-Fc from 
26.0 times in the initial ligand soak to 621.6 times, as this would greatly increase the chances of the 
heparin binding to the IgG-Fc as any available binding sites would be saturated. The differences in 
this new strategy were as follows: Firstly the ligand used was a rough fraction of heparin of higher 
mass (5.5 KDa ± 10%) than the purified dp12 fraction used in the initial soaking trial. Secondly, the 
IgG-Fc was soaked with a much higher concentration of this ligand (95 mM as opposed to the 
original 10 mM). The final difference was the inclusion of a low level (50 mM) of the same sodium 
acetate buffer that was used to reconstitute the protein. The addition of the acetate was to assist the 
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heparin in binding to the IgG-Fc, this was performed because of the results of the preliminary circular 
dichroism experiment which showed a change in the secondary structure of the IgG when in the 
presence of the heparin and a low level of the acetate (Hadfield 2018 A shrive 2017, personal 
communication, 15 November). A recombinant IgG1-Fc, which was purified from human sera was 
used in the ligand soak trials. This is because the amino acid sequence of this recombinant protein 
was known (Fig. 4.3.1). 
Ligand soaking trials were performed in order to determine the effect of ligand concentration on the 
stability of the crystals; as well as to determine an appropriate amount of time for the crystals to be 
soaked in the ligand without destabilising them. The crystals chosen for the soaking trials were 
picked due to their small size and irregular shape which made them inadequate for use in data 
collection. The crystals were monitored closely in the minutes following the addition. As well as 
being monitored twice daily in the week after the addition of the heparin and the sodium acetate with 
observations and pictures being taken at key times throughout the week (See Appendix 2). The key 
observation being that the crystals showed no major changes in their size or shape during the trial 
which meant that either the heparin was taken up readily by the crystals and did not disturb them; or 
that the heparin did not interact with them at all.  
However, when this new soaking strategy was tried in the wells of interest (HE4A1, HE4A2, HE4C1 
and HE5A1) the crystals started to rapidly degrade upon the addition of the 77% glycerol that was 
required for cryoprotection, or after the addition of 50 mM sodium acetate (which was the same 
buffer that the protein was initially prepared in). This degradation was most likely caused by the 
crystals going into shock either from the acetate having a much larger than anticipated effect on the 
conditions or from the heparin being taken up by the crystals. Out of these five wells crystals could 
only be collected from HE4C1 and HE5A1, eight crystals were collected from HE4C1. However, 
only one of the crystals collected from HE4C1 was exposed to the acetate. This was due to the rapid 
degradation of the crystals following the addition. Only one crystal was collected from HE5A1 
because the well rapidly degraded after cryoprotection. The conditions for these wells are shown in 
table 4. 
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Table 3.2 – Table of well conditions for wells HE3A1, HE4A1, HE4A2, HE4C1, HE4C2 and HE5A1. 
HE3A1 0.1 M HEPES pH 7.5 
16% PEG 6000 
HE4A1 0.1 M MES pH 6.1 
16% PEG 3350 
HE4A2 0.1M MES pH 6.1 
18% PEG 3350 
HE4C1 0.1 M MES pH 6.5 
16% PEG 3350 
HE4C2 0.1 M MES pH 6.5 
18% PEG 3350 
HE5A1 0.1 M MES pH 6.3 
18% PEG 3350 
 
3.3.3.2  Data Processing and Selection 
Four datasets were collected from eight heparin soaked crystals, only one of which had been exposed 
to acetate. Of these four datasets only two of them were used for data analysis, because the other two 
datasets were not suitable for use. This was because the images produced during X-ray diffraction 
of the crystals did not contain enough information and as a result, they could not be processed.  
The datasets were integrated and refined by the MOSFLM program; after which they were scaled 
and merged into an average intensity using the Pointless-Aimless pipeline which also determined 
the unit cell parameters alongside the spacegroup. Of the original four datasets, only two of them 
were able to be further processed using the Truncate program. The details of the processed data 
statistics for the two datasets are included in table 4.3.1. The remaining two datasets were not taken 
forward due to the MOSFLM program not being able to process them. Both of these datasets were 
taken forward in the hope of them giving some detail of the heprin binding properties of IgG-Fc.  
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Table 3.3 – Initial Data Processing of the recombinant IgG1-Fc Datasets 
 Ligand soaked 
recombinant IgG-
Fc (HE4_C18) 
Ligand soaked 
recombinant IgG-
Fc (HE4_C19) 
Data Collection   
Synchrotron Station I04 I04 
Wavelength (Å) 0.9795 0.9795 
Space Group P 21 21 21 P 21 21 21 
Cell Dimensions (Å) a = 49.889  
b = 79.641  
c = 138.078        
a = 49.249  
b = 79.945  
c = 138.183        
   
   
Resolution Range 
(Å) 
79.88 – 3.60 
(3.60 – 3.60) 
79.88 – 3.89 
(3.55 – 3.55) 
Observations 286360 40360 
Unique Reflections 41514 6627 
Completeness (%) 95.1 (79.4) 95.3 (89.9) 
Rmerge  0.113 (0.407) 0.118 (0.429) 
CC1/2 0.979 (0.520) 0.980 (0.540) 
Mean (I/σ(I)) 11.0 (4.8) 10.7 (4.7) 
   
Refinement   
Protein Atoms 7008 7008 
Residues (Chain A) 206 204 
Residues (Chain B) 207 208 
Water Molecules 0 0 
   
Rwork (%) 0.3249 0.2493 
Rfree (%) 0.2966 0.3007 
Figures in parentheses refer to the highest resolution bin.  
a Rmerge = ΣhΣj | Ih,j – Ih | / ΣhΣj | Ih,j|, where Ih,j is the jth observation of reflection h and Ih is the mean of the j measurements of 
reflection h.  
b Rwork = Σh | |Foh| - |Fch| | / Σh |Foh|, where Foh and Fch are the observed and calculated structure factor amplitudes, respectively, 
for reflection h.  
c Rfree is equivalent to Rwork for a randomly selected subset (5%) of reflections not used in the refinement. 
d Determined according to MolProbity. 
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3.4  Discussion 
3.4.1  Quality of the structural data 
The final density map produced after several rounds of refinement had identified all the key structural 
components of IgG1-Fc; including the detailed structure of the N-linked glycan to the point where 
the glycoform of IgG-Fc could be determined.  
3.4.2  Significance of the visible structural components of IgG-Fc 
3.4.2.1  Analysis of the Structural Discrepancies Seen in the Reported Structure  
The CH2 domain already has some degree of movement between IgG glycoforms afforded to it by 
the differences in the length and composition of its N-linked glycan as well as the innate flexibility 
of the hinge region. And many of these conformations have been well documented. However none 
of the conformational differences within these other structures are as large as the change seen in the 
reported structure.   
The CH2 domain is also known to change conformation once the C1q complement protein has bound 
to the Fc region, with the CH2 domains changing from an open conformation (Where the two CH2 
domains are at a maximal distance from each other) to a closed conformation (where the two CH2 
domains are at a minimal distance to each other) as has been documented by (Mimura et al., 2001; 
Mimura et al., 2011; Gaboriaud et al., 2003). This could explain the change in conformation seen in 
the reported structure as being a product of the heparin binding to the IgG-Fc as it is feasible that 
this has caused the change. The reason that the heparin is not visible in this structure could be that it 
was not at a high enough concentration to be seen in all of the IgG-Fc molecules in the lattice, but 
was at a high enough concentration to have a visible effect. It could also be possible that the heparin 
was not held rigidly within the structure and as a result did not produce any density. The most likely 
explanation for the large shift in the CH2 domain is that it was caused by an artefact of the actual 
crystallisation process itself, potentially caused by the fact that the protein stock contained a mixture 
of the four IgG Isoptypes which are of different lengths. 
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3.4.2.2  Difficulty with producing a heparin bound structure 
A heparin bound structure has not been produced by the crystals which had been soaked in either the 
dp12 ligand or in the rough heparin fraction. Despite the fact that the required molar excess of 
heparin is unknown, this is unlikely to be due to a low molar difference between the heparin and the 
IgG for the rough fraction because there was 621.6 times the amount of heparin in the well than IgG-
Fc. This could however explain why the dp12 ligand did not bind to the IgG-Fc as there was only 
26.0 times the amount of dp12 in HE2A2 than IgG-Fc and as such any potential binding sites on 
IgG-Fc might not be sufficiently saturated for the dp12 to be visible within the structure. It is also 
possible that the heparin takes longer to bind to the IgG-Fc than the 38 minutes it was given in 
HE2A2 or the 36 minutes it was given to soak in HE4C1. The crystals dissolving could also have 
been caused by the heparin entering the binding site within the native crystals and disrupting their 
structure from within. This could also explain why some of the crystals appeared to be stable during 
soaking, because in these instances the heparin could have been unable to enter the binding site and 
as such did not disrupt the structure. 
3.4.3  The varying success of the Crystallisation and Heparin Soaking Trials 
The varying degrees of success when it came to growing and cryo protecting the crystals of the IgG-
Fc were well noted from the beginning of the study and were persistent throughout the study, with 
different crystals from the same well or even crystals with the same mother liquor conditions 
produced crystals which reacted differently to the chosen cryoprotectant as well as the heparin 
ligand. It was noted that there were two main crystal forms favoured by the IgG-Fc crystals; one of 
which was short, wide rods which sometimes had pointed ends, as well as a second crystal form 
which was a shower of small jagged crystals. These two crystal forms were not mutually exclusive 
to a particular condition. In the case of HE2A2, both of the crystal forms were found in the well. 
These two crystal forms also appeared to have different stability when the acetate was introduced: 
HE3A1 which contained a shower of jagged rods, was completely stable for well over three weeks 
after the addition of 30.7 mM Heparin and 50mM sodium acetate to the well. The details of this soak 
can be found in Appendix 2. However, once the acetate was added to HE4C2 which contained 
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several of the larger single crystals the crystals rapidly degraded with most of the smaller crystals 
dissolving completely. The results of this soak can be found in Appendix 3.  
These differences could also be due to the way in which the wells were cryoprotected: The 
concentration of glycerol in HE2A2 was slowly built up with six 2 µl volumes of glycerol, whose 
concentrations ranged from 5% - 30% before 12 µl of the mother liquor was exchanged for the 30% 
solution (all solutions were made up to concentration using well conditions) to give a final glycerol 
concentration of 25%. Whereas HE4C1 was cryoprotected using four 0.5µl additions of 50% 
glycerol which gave a final glycerol concentration of 22% and caused the crystals to rapidly degrade. 
The 50% additions may have been too great of a shock to the crystals because of the glycerol being 
wildly different to the mother liquor and as such the crystals degraded.  
Another explanation for the difference in crystal stability is that the well conditions of HE3A1 were 
different from both HE2A2 and HE4C1 as can be seen in table 5. The higher pH (7.5) of the HEPES 
buffer could have produced more stable crystals. 
Table 3.4 – Table of well conditions for well HE3A1 and HE4C1. 
HE3A1 0.1 M HEPES pH 7.5 
16% PEG 6000 
HE4C1 0.1 M MES pH 6.5 
16% PEG 3350 
 
During data collection on these crystals, the presence of ice-rings in the diffraction images made it 
apparent that the crystals had not been completely cryoprotected. This shows that ice had built up 
inside of the crystal causing damage to the lattice. This is also likely to have contributed to the low 
resolution and poor processing of these datasets as well as the poor electron density observed during 
refinement. 
3.4.4  Quality of the Structural Data 
After several rounds of refinement, all of the electron density for the protein backbone was present 
in the density map. However, the density for some of the side chains was not fully defined and as 
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such; the confidence of the fitting in these areas is not high. Much of the fine details of the structure 
of the N-linked glycan was also lost in this structure for example the fucose0 residue, however there 
was enough density to confidently model the glycan into the structure.  
3.4.5  Analysis of the Key Structural Details 
The structural details which can be observed in the protein backbone of this heparin soaked structure 
of recombinant IgG1-Fc are identical to the native structure of IgG1-Fc from human sera. This was 
confirmed when the model of native IgG1-Fc fit perfectly into the density map of the heparin soaked 
IgG1-Fc. Further refinement of this density map did not result in any changes to the density of the 
backbone, but did result in slight improvements to the density for the N-linked glycan. In both 
structures the conserved C1q binding cleft which is formed by the two CH3 domains was clearly 
visible. In addition to this, there was clear density for all of the identifying residues that would 
typically be expected to be seen within the structure of IgG1-Fc, some examples of these are shown 
in figure 3.6 below.  
 
Figure 3.6 – Examples of the electron density fitting for some of the identifying residues of the native 
IgG-Fc. (A) The electron density fitting for Leu234 and Leu235. (B) The electron density fitting for Tyr296. 
Leu235 
Leu234 
Tyr296 
(A) (B) 
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No electron density was visible for the heparin ligand in this structure. There was also no evidence 
present for the heparin binding activity that was reported in the initial CD experiments. This can be 
explained by the lack of structural differences between the structure of native IgG1-Fc and the 
structure of heparin soaked IgG1-Fc; because it can be expected that the reported secondary structure 
change would result in an obvious change to the quaternary structure which would be visible when 
the density of the heparin soaked IgG1-Fc was compared to the model of native IgG1-Fc. As this 
was not the case it can be concluded that heparin has not bound in the heparin soaked model. This 
could be due to there not being a great enough excess of heparin used in the soak, and as such the 
heparin was not at a high enough concentration to bind. Or more likely, it is because the secondary 
structure of IgG1-Fc cannot change once it has been locked in place in the crystal matrix and as such 
heparin cannot bind successfully.  
3.4.6 Protein Electrostatics and Potential Heparin Binding Sites 
Electrostatic analysis of the reported protein structure of the native IgG-Fc from sera revealed several 
highly positively and negatively charged regions (these regions can be seen in full in figure 3.7 B 
and C below). This analysis also revealed two grooves with an overall positive charge; the first of 
these grooves is made up of the CH3 domains of both the A and B chains and is made up from the 
Ser354 – Ser400 residues of both chains. The second groove was found to be within the empty space 
between the A and B chains that is occupied by the N-linked glycan. The first groove is known to be 
the binding site of C1q during the activation of the complement cascade. Due to the highly negative 
charge produced by the various S-domains within the structure of heparin; it has been observed that 
heparin tends to bind to highly positive grooves, such as the two examples mentioned above. This 
potentially implies that these two positive grooves could act as potential binding sites for heparin. 
However, due to the size of these grooves in comparison to dp12 heparin, it is likely that any 
interaction could be between IgG-Fc and a shorter heparin polymer. A potential way to test this 
theory would be to attempt to produce crystals of IgG-Fc bound to singular sulphate ions. 
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Figure 3.7 – The structure packing and electrostatics of the produced Native IgG-Fc structure. (A) The 
packing of the reported protein structure, the packing of the A chain is shown in light blue and the packing of 
the B chain is shown in light brown. (B) The electrostatics of the full structure of the reported native IgG-Fc 
from sera; areas of positive charge are shown in red and areas of negative charge are shown in blue. (C) The 
electrostatics of the groove formed by the CH3 domains of the A and B chains; areas of positive charge are 
shown in red and areas of negative charge are shown in blue. 
(A) 
(B) 
(C) 
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3.5  Conclusion 
The main aim of this work was to determine the binding mechanism for the interaction between IgG-
Fc and the heparin dp12 polymer and how this interaction modifies the structures of both of these 
molecules. The results presented here show the findings of the initial work into the characterisation 
of the dp12 – IgG-Fc interaction. So far only the native structure of IgG-Fc has been produced, this 
was due to the dp12 ligand not successfully binding to IgG-Fc because the well conditions may have 
been incorrect for this interaction. As such, the ligand could not alter the crystal matrix and enter the 
binding site.  
Immediate work to produce a ligand bound would include further optimisation of the ligand soaks 
and cryoprotection protocols, in order to prevent the rapid crystal degeneration seen in these trials. 
This work would be followed by co-crystallisation screens of the recombinant IgG-Fc fragment with 
the rough heparin fragment if further optimisation of the soak protocol failed to provide usable results 
(Clark et al, 1993; Nikolov et al, 1993). Once either the ligand soaking protocol or the co-
crystallisation protocol had produced results with the rough fraction the protocol would then be 
repeated with the dp12 ligand.   
Additionally, after a heparin bound structure had been produced, further work would look to 
determine whether a change in the chain length of the heparin polymer effects the binding affinity 
of IgG-Fc for heparin. The final goal of this work would be to look into what effect the heparin-IgG-
Fc interaction has on the binding affinity of IgG-Fc to some of its immune receptors such as C1q, 
FcγR and FcγRn (Gaboriaud et al. 2003). 
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Chapter 4 – General Discussion, Conclusions and Future Work 
The work presented in this thesis aims to increase the current knowledge of the binding mechanisms 
of IgG-Fc by presenting a heretofore unobserved association with analogues of heparin through 
structural studies of native IgG-Fc purified from human sera and a recombinant IgG1-Fc soaked with 
heparin. Whilst the crystals reported in this work are an advancement to understanding this 
interaction between heparin and IgG1-Fc as preliminary work as they form a reliable basis for further 
structural studies to be undertaken.  
4.1  Crystal Forms and Condition Choice 
Two crystal forms were observed during the crystallisation trials described in this work. The first 
form was large flat singular rods which either had pointed or flat ends and the second form was a 
large shower of much smaller rods which only had pointed ends. During the cryoprotection and 
soaking trials it was determined that only the larger rods with flattened ends were completely stable 
when exposed to both the cryoprotectant and the ligand. The larger rods with pointed ends would 
either completely or partially degrade when exposed and the smaller rods would consistently degrade 
completely. The large pointed rods degraded inconsistently between wells with repeat and similar 
conditions, in some wells they would degrade completely and in others they would only partially 
degrade. The reason for the large pointed rods degrading when exposed to the ligand may well be 
because of the ligand entering the crystal and interacting with the IgG-Fc molecules and disrupting 
the crystal lattice. This could also explain why the flattened rods did not degrade when exposed to 
ligand as none of the structures produced by ligand soaked crystals showed heparin binding which 
indicates that heparin has not entered the crystal structure. Examples of these crystal forms as well 
as ligand soaking and cryoprotection trials can be found in appendix 2.   
4.2  Ligand Soaks and Co-Crystallisation 
The reason for initially soaking the crystals, rather than co-crystallising was to preserve the limited 
stocks of both protein and ligand; whilst establishing conditions in which the crystals could survive 
when exposed to the ligand. During these ligand soaking trials many of the crystals degraded and 
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dissolved rapidly upon addition of the ligand. However this seemed to be largely dependent on the 
crystal forms that were exposed to the ligand; with the smaller, sharper crystal showers dissolving 
much more rapidly than the larger rods. Once a viable condition had been established by the soaking 
trials, a co-crystallisation approach was turned to. This method was utilised primarily because none 
of the ligand soaked crystals (which did not dissolve), did not produce ligand-bound structures. This 
was thought to because the secondary structure of IgG-Fc was require to undergo a conformational 
change in order to bind heparin, which could not occur once the protein was locked in place in a 
crystal lattice. This approach also allows for longer ligands (such as dp12 heparin) to enter into the 
protein, which they are unable to do in some crystal forms due to the way in which the proteins are 
arranged in the crystal lattice.  
4.3  N–Linked Glycan 
The IgG-Fc purified from human sera was reported to be of the G1F glycoform, where the G refers 
to the number of galactose residues and 1F refers to the number and position of fucose residues (one 
fucose bound to GlcNAc at position 1). This glycoform is present in roughly 38% of all IgG-Fc in 
human sera and whilst it is possible that the reported structure could be of a different glycoform there 
was not enough density to suggest this. The electron density for both chains at the Asn297 residue 
was very clear. However, there was no density to indicate that a bisecting GlcNAc or terminal sialic-
acid residue were present. The electron density was much clearer for the α1-6 arm of the A-chain N-
linked glycan and as such accurately reporting the orientation of the fucose and galactose residues 
in the B-chain was more difficult. However, these residues were still present as there was partial 
density for them and the two glycans must identical. Privateer (Agirre et al. 2015), reported that the 
ring of the GlcNAc1 in the A chain glycan was slightly puckered and as a result was not in a 
thermodynamically favourable orientation. However, after several rounds of refinement, this was 
determined to be acceptable as altering the orientation of this residue would cause the rest of the 
glycan to enter unfavourable orientations.  
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4.4  Practicality of Mass Spectrometry 
Mass spectrometry techniques were utilised alongside x-ray crystallographic analysis of the structure 
to aid in the correct identification of the isoform of IgG-Fc that was present in the protein crystals. 
Trypsin and GluC were both required in order to give the greatest sequence coverage as they have 
differential splicing patterns and so produced different sequences. This meant that the GluC samples 
were able to produce sequences that the trypsin samples could not and vice versa.  
Because ESI and MALDI produce fragments of different lengths (with MALDI producing longer 
sequences and ESI producing shorter sequences), it was possible to produce a greater range of 
fragments and therefore a greater sequence coverage. These techniques proved to be effective 
companions to x-ray diffraction as they were able to determine which isoforms of IgG1-Fc, IgG2-
Fc, IgG3-Fc and IgG4-Fc were present in the sample of human sera. This was possible, because 
whilst the sequence of IgG-Fc is 90% conserved between the isoforms, there are a series of 
identifying residues which are not conserved which were observed by this technique.  
4.5  Implications and Future Work 
Immunoglobulins are a key component of the immune system of vertebrates due to their ability to 
identify pathogens and activate other components of the immune system. IgG-Fc is critical to the 
function of IgG as an activator of the immune system because of the interactions between it and the 
cell-surface receptors of immune cells. The conditions described in this thesis offer the potential to 
be used as a foundation for further crystallisation trials into the novel interaction of human IgG-Fc 
and heparin. Once a heparin bound structure is produced, the work would need to focus on fully 
characterising the interaction and any conformation changes within IgG-Fc. Additionally, following 
the production of a dp12 heparin bound structure, the next step would be to determine whether a 
change in the chain length of the heparin analogue effects the binding affinity of IgG-Fc for heparin. 
Once this has been established, the final goal would be to look into what effect, if any the heparin-
IgG-Fc interaction has on the binding affinity of IgG-Fc to cell-surface receptors such as C1q, FcγR 
and FcγRn (Gaboriaud et al. 2003), as well as whether the interaction affects the pathogen binding 
properties of IgG-Fc.
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Appendix 1 – Full ESI result Tables 
Table 1. The mass spectrometry data for the sequences of the IgG3 Fc fragment produced by the MS/MS analysis of a GluC digest performed on the 
Purified human serum IgG Fc Fragment (P80-204). 
Start   End Observed Mr(expt) Mr(calc)  ppm Miss
  
Score Expect Rank U  Peptide 
117 – 141 685.8033 2739.1842 2739.5033 -116 1 99 1.1e-007 1  E.LLGGPSVFLFPPKPKDTLMISRTPE.V 
117 – 141 914.0761 2739.2064 2739.5033 -108 1 158 1.2e-013 1 
 
E.LLGGPSVFLFPPKPKDTLMISRTPE.V 
117 – 141 689.8008 2755.1740 2755.4983 -118 1 78 1.3e-005 1 
 
E.LLGGPSVFLFPPKPKDTLMISRTPE.V + 
Oxidation (M) 
117 – 141 919.4057 2755.1952 2755.4983 -110 1 130 9e-011 1 
 
E.LLGGPSVFLFPPKPKDTLMISRTPE.V + 
Oxidation (M) 
142 – 155 792.7769 1583.5393 1583.7138 -110 2 67 0.00019 1 
 
E.VTCVVVDVSHEDPE.V 
241 – 265 966.3943 2896.1610 2896.4681 -106 2 72 5.3e-005 1 U E.LTKNQVSLTCLVKGFYPSDIAVEWE.S 
Table 2. The mass spectrometry data for the sequences of the IgG1 Fc fragment produced by the MS/MS analysis of a GluC digest performed on the 
Purified human serum IgG Fc Fragment (P80-204). 
Start   End Observed Mr(expt) Mr(calc)  ppm Miss
  
Score Expect Rank U  Peptide 
106 – 137 880.6046 3518.3894 3518.7764 -110 1 66 0.00022 1 U E.CPPCPAPPVAGPSVFLFPPKPKDTLMISRTPE.
V + Oxidation (M) 
138 – 151 792.7769 1583.5393 1583.7138 -110 2 67 0.00019 1 
 
E.VTCVVVDVSHEDPE.V 
Start   End Observed
   
Mr(expt) Mr(calc)    ppm   Miss
  
Score Expect Rank U  Peptide 
164 – 188 685.8033 2739.1842 2739.5033 -116 1 99 1.1e-007 1  E.LLGGPSVFLFPPKPKDTLMISRTPE.V 
164 – 188 914.0761 2739.2064 2739.5033 -108 1 158 1.2e-013 1 
 
E.LLGGPSVFLFPPKPKDTLMISRTPE.V 
164 – 188 689.8008 2755.1740 2755.4983 -118 1 78 1.3e-005 1 
 
E.LLGGPSVFLFPPKPKDTLMISRTPE.V + 
Oxidation (M) 
164 – 188 919.4057 2755.1952 2755.4983 -110 1 130 9e-011 1 
 
E.LLGGPSVFLFPPKPKDTLMISRTPE.V + 
Oxidation (M) 
189 – 202 792.7769 1583.5393 1583.7138 -110 2 67 0.00019 1 
 
E.VTCVVVDVSHEDPE.V 
288 – 312 972.3779 2914.1119 2914.4245 -107 2 92 6.8e-007 1 U E.MTKNQVSLTCLVKGFYPSDIAVEWE.S 
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Table 3. The mass spectrometry data for the sequences of the IgG2 Fc fragment produced by the MS/MS analysis of a GluC digest performed on the 
Purified human serum IgG Fc Fragment (P80-204). 
Observed Mr(expt) Mr(calc) ppm Miss  Score Expect Rank Peptide 
790.8323 1579.6501 1579.7334 -52.75 1 22 8.5 1 MLRSGANDLGGTLME + Oxidation (M) 
876.8673 1751.7200 1751.8400 -68.50 1 16 29 1 ALDLCYQTSQLAGIAE 
679.7405 1357.4665 1357.6878 -163.00 1 16 28 1 WNEGTIVVKSPE 
584.9051 1751.6936 1751.8764 -104.33 2 13 57 1 SMIFQTEKQLKDLGD 
844.0205 2529.0396 2529.3525 -123.71 1 12 51 1 IQRFILRSLGEKRQLYYAME + Oxidation (M) 
713.6000 2137.7781 2137.9959 -101.86 1 10 99 1 SGDVLLMHLGMSGSFRVAMD + Oxidation (M) 
794.3075 1586.6004 1586.8491 -156.70 1 10 1.4e+002 1 FLARVPENVVVVMD 
838.6910 2513.0512 2513.2656 -85.30 2 9 1.2e+002 1 KSKNSLEDQPNAQKALAIQCRD 
1162.8065 3485.3977 3485.9227 -150.62 0 8 1.7e+002 1 TRPLKHKWRPSPLLVMQRNSSVPNLKMKE + Oxidation (M) 
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Appendix 2 – Heparin Soaking and Cryoprotection Trials 
 
 
Volume Added Time Comments 
0.5 µl, 95 mM heparin.  09:00 Heparin added- coverslip 
broke however no glass 
entered the well. 102-6762 
 09:10 No change. 102-6773 
 09:20 No change. 102-6776 
 09:30 No change. 102-6777 
 09:40 There appears to be some 
loss of width in some of the 
very small crystals. 102-
6783 & 102-6785 
 09:50 No change. 102-6786+6787 
0.5µl, 95 mM heparin. 10:00 Second addition. 102-6793 
 10:10 No change. 102-6815 
 10:20 No change. 102-6816 
 10:30 No change. 102-6819 
 10:40 No change. 102-6834 
 10:50 No change. 102-6837 
 11:00 No change. 102-6852 
Tray Number HE3A1 
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 11:20 No change. 102-6881 
 11:40 No change. 102-6885 
 12:00 No change. 102-6895 
 12:30 No change. 102-6901 
 13:00 No change. 102-6903 
 13:30 No change. 102-6905 
 14:00 No change. 102-6907 
 15:00 No change. 102-6910 
 16:00 No change. 102-6914 
 17:00 No change. 102-6921 
Wednesday 10:00 No change. 102-6940 
 16:00 No change. 102-6950 +       
102-6953 
Thursday 10:00 No change. 102-6965 
0.1 µl, 1.55 M Na Acetate pH 
4.5 added (Final concentration 
50 mM). 
11:00 Crystals Stable. 102-6967 
 11:10 No change. 102-6969 
 11:20 No change. 102-6972 
 11:30 No change. 102-6974 
 11:40 No change. 102-6975 
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 11:50 No change. 102-6977 
 12:00 No change. 102-6978 
 12:20 No change. 102-6983 
 12:40 No change. 102-6985 
 13:00 No change. 102-6986 
 13:30 No change. 102-6991 
 14:00 No change. 102-6991 
 15:00 No change. 102-7003 
 16:00 No change. 102-7004 
 17:00 No change. 102-7008 
Friday 10:00 No change. 102-7013 
 16:00 No change. 102-7016 
Saturday 10:00 No change. 102-7017 
 16:00 No change. 102-7018 
Monday 10:00 No change. 102-7019 
 16:00 No change. 102-7021 
Tuesday 10:00 No change. 102-7022 
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102-6762                                                         102-6773 
  
102-6776                                                         102-6777 
  
102-6783                                                         102-6785 
  
102-6786                                                         102-6787 
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102-6793                                                         102-6815 
  
102-6816                                                         102-6819 
  
102-6834                                                         102-6837 
  
102-6852                                                         102-6881 
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102-6885                                                         102-6895 
  
102-6901                                                         102-6903 
  
102-6905                                                        102-6907 
  
102-6910                                                         102-6914 
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102-6921                                                         102-6940 
  
102-6950                                                         102-6953 
  
102-6965                                                        102-6967 
  
102-6969                                                         102-6972 
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102-6974                                                        102-6975 
  
102-6977                                                         102-6978 
  
102-6983                                                         102-6985 
  
102-6986                                                        102-6991 
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102-6992                                                         102-7003 
  
102-7004                                                        102-7008 
  
102-7013                                                        102-7016 
  
102-7017                                                         102-7018 
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102-7019                                                         102-7021 
 
102-7022 
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Well Number HE4C2 
 
Volume Added Time Comments 
0.5 µl 95 mM heparin 11:00 Heparin added to the well. The crystals 
are stable. 
0.5 µl 0.30 M Na Acetate pH 4.5 11:05 Acetate added to the well. The crystal 
directly under the addition site 
dissolved almost immediately. 
 11:08 Some of the crystals dissolved rapidly 
with some of the smaller ones 
dissolving completely 
 11:10 There was a further reduction in crystal 
size. 
 11:12 Most of the crystals at the top of the 
drop had dissolved by this point 
however there are some which seem 
unchanged. 
 11:14 Even more degradation of the crystals 
with some of the larger ones breaking 
up. However some of the larger daggy 
one seem fine. 
 11:16 No change. 
 11:18 One of the crystals at 10 o’clock which 
looked stable has started to dissolve 
slightly. 
 11:20 No change. 
 11:22 No change. 
 11:24 A slight reduction in size in some of the 
more shrivelled crystals. 
 11:26 No change 
 11:28 No change 
 11:30 No change 
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 11:32 The crystals which were stable to begin 
with remained so but the ones which 
were dissolving started to get even 
worse. 
 11:34 No Change. 
 12:30 The well seems to have stabilised. 102-
7051. 
0.5 µl 50 % Glycerol added 13:40 
Crystals dissolved by 1347. 
0.5 µl 50 % Glycerol added 13:40:30 
0.5 µl 50 % Glycerol added 13:41 
0.5 µl 50 % Glycerol added 13:41:30 
 
 
 
 
 
 
 
 
Appendix 2 
Page 139 of 141 
 
 1100  
Heparin 
1105 
Acetate 
1
1
1 1
1 1
1100 
No 
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1 1
1 1
1 1
1 1
Appendix 2 
Page 141 of 141 
 
 
 
 
This trial was performed due to the dissolving of the larger xtals within wells: HE4A2 and 
HE4C1 during xtal freezing on 04/07/18 after a ligand soak trial on smaller xtals in well HE3A1 
with the same concentrations and volumes (1 µl 95 mM heparin and 0.1 µl 1.55 M Na Acetate 
pH 4.5) showed that the xtals were stable after these additions. 
 Make up 1 ml of 0.30 M Acetate stock using 100 µl of the 3 M stock and 900 µl of 
filtered deionised H2O.  
 Add 0.5 µl of 95 mM heparin stock and observe to make sure well is stable. 
 Wait 5 minutes and add 0.5 µl of the 0.35 M stock of Acetate and observe whether 
crystals dissolve and/or how long that takes. 
 Adding these two volumes would reduce the protein concentration to 0.051 mM and the 
heparin concentration to 15.8 mM. This would give a molar fold difference of 385.4 
before the addition of any cryo buffer.  
 
1 1
11
